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ABSTRACT 
 
Chambers-Turner, Ruth M.S., Microbiology and Immunology Graduate Program, Wright 
State University, 2010. The IM-9 cell line: a model for evaluating TCDD-induced 
modulation of the polymorphic human hs1,2 enhancer within the 3’ immunoglobulin 
regulatory region. 
 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a disrupter, of B-cell differentiation, 
induces binding of the aryl hydrocarbon receptor (AhR) nuclear complex to dioxin 
responsive elements (DRE) within the mouse immunoglobulin heavy chain regulatory 
region (3’IgHRR), and produces a marked inhibition of 3’IgHRR activation, IgH 
expression, and antibody secretion in a well-characterized mouse B-cell line (CH12.LX). 
The mouse 3’IgHRR consists of at least four enhancers (hs3a; hs1,2; hs3b; hs4), and is 
highly homologous with the three enhancers (hs3; hs1,2; hs4) of the human 3’IgHRR. A 
polymorphism of the human hs1,2 enhancer (resulting in varying numbers of tandem 
repeats containing a DRE and κB site) has been correlated with several autoimmune 
diseases. Although the human and mouse hs1,2 enhancers are share a ~90%  identity, 
luciferase reporter studies in mouse CH12.LX B-cells showed that TCDD inhibited LPS 
stimulation of the mouse hs1,2 enhancer but co-treatment with TCDD and LPS 
synergistically activated human hs1,2 enhancer activity. To evaluate transcriptional 
differences between the human and mouse hs1,2 enhancers, our objectives were to 
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characterize the IM-9 cells as a potential human B-cell model, and to evaluate TCDD-
induced transcriptional regulation of the polymorphic human hs1,2 enhancer in a human 
cell line. We confirmed AhR expression and TCDD-induced CYP1A1 induction in IM-9 
cells. Then we transiently transfected IM-9 cells with the human hs1,2 reporters and 
determined that TCDD activates the human hs1,2 enhancer in IM-9 B-cells, as seen in 
CH12.LX B-cells. However, the TCDD-induced fold-activation in human IM-9 cells 
appeared less compared to results in mouse CH12.LX B-cells perhaps due to differences 
between the mouse and human AhR. Our data suggests that the TCDD-induced inhibition 
of the mouse hs1,2 enhancer versus the activation of the human hs1,2 enhancer may be 
related to an inhibitory BSAP site located on the mouse hs1,2 enhancer that is absent 
from the human hs1,2 enhancer. Our results support the use of IM-9 cells as a model for 
studies evaluating mechanistic differences between the mouse and human hs1,2 
enhancers. 
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INTRODUCTION 
 
 
Overview of B-cell and immunoglobulin development 
2-3-7-8-tetrachlorodibenzo--dioxin (TCDD) is a potent environmental 
contaminate that has demonstrated toxic effects in laboratory animals and humans. One 
of the most sensitive targets of TCDD is B cells in which TCDD inhibits expression of 
the immunoglobulin heavy chain gene (IgH) and secretion of immunoglobulin (Ig) in 
activated mouse B cells (Sulentic et al., 1998; Sulentic et al; 2000; Dooley and 
Holsapple, 1988; Karras and Holsapple, 1994). Immunoglobulin, also known as antibody 
(Ab), is composed of two identical heavy and light chains, each containing a constant and 
variable region. The composition of the heavy and light chains is generated in a complex 
sequence of events resulting in genetic rearrangement of the immunoglobulin heavy 
chain (IgH) and light chain (IgL) genes from their germline configurations.  Specifically, 
a single variable (V), diversity (D) (only for IgH), and joining (J) region will be 
recombined to form the VDJ variable region of IgH and the VJ variable region of IgL.  
V(D)J recombination of the light and heavy chains will confer antigen specificity of the 
antibody. The IgH gene contains several constant (C) regions that encode each of the five 
major classes of antibody (IgM, IgD, IgG, IgA, IgE). A DNA recombination event called 
class switch recombination (CSR) will determine which isotype is expressed. 
Rearrangement of the VDJ regions and early IgM expression in the cytoplasm occurs 
during the first stages of B cell maturation from precursor stem cells to Pro then Pre-B 
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cells (Fig. 1). During the next phase, the immature B cell stage, early IgM is expressed on 
the surface of the cell (Fig. 1). In the following mature B cell phase, both IgM and IgD 
are expressed on the cell membrane (Fig. 1). Notably, if a B cell fails a step in the 
maturation process or recognizes a self antigen, it goes through negative selection, and 
will die by apoptosis. Mature B cells can bind antigen through their membrane bound Ig 
which is called the B-cell receptor (BCR). The B cell will not differentiate further until it 
has been activated by antigen (Ag). Activation initiates stimulatory pathways that result 
in regulation of class switch recombination (CSR), proliferation, and Ig expression and 
secretion. Activation can be initiated in a T-independent or T-dependent manner. In T-
independent activation a T-independent antigen binds to the BCR or a toll-like receptor 
on the B cell membrane. An example of a T-independent antigen is lipopolysaccharide 
(LPS), a cell wall component of gram negative bacteria that can, in higher doses, induce 
polyclonal activation and antibody secretion by binding to TLR4 or a LPS-specific BCR. 
Activation with a T-dependent antigen requires that first the T-dependent antigen binds to 
the BCR. The antigen is then engulfed and digested into peptides that are subsequently 
displayed on the B cell surface by major histocompatibility complex II (MHC II) 
molecules. Then the MHC II/antigen is cross-linked by a CD4+ T-cell receptor along 
with an additional stimulatory interaction between the CD40 receptor on the B cell and 
CD40 ligand (CD40L) on the T-cell. Activation of a B cell induces a signal transduction 
pathway that causes B cell proliferation and differentiation to high antibody producing 
plasma cells or memory B cells (Fig. 1). After a B cell has been activated, additional 
BCR diversity for antigen can still be generated by somatic hypermutation, in which 
single nucleotides of the already rearranged VJ or VDJ regions are randomly exchanged 
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with different nucleotides. Additionally, after B cell activation, CSR can change the 
isotype of the expressed immunoglobulin. During CSR double stranded DNA is 
enzymatically broken in two of the repetitive sequence regions, termed switch regions 
(S), that are associated with each constant region. Then, the segment in between the two 
broken S regions, one located upstream of the first constant region and one located 
upstream of the constant region that will be expressed following CSR, is deleted out of 
the gene and the VDJ is joined to the switched constant region. Throughout the CSR 
process the IgH chain maintains its VDJ sequence, and therefore, variable region antigen 
specificity remains unchanged. However, a new constant region will be expressed which 
will reflect a change in isotype.  As Ig is the key effector molecule of the B-cell-mediated 
immune response, TCDD-induced modulation of Ig expression and secretion is highly 
significant. Normal Ig expression and secretion is in part, dependent on the complex 
organization of the IgH gene.  
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Figure 1. B-cell maturation, differentiation, and Ig expression. B cells mature 
independent of antigen from precursor stem cells to IgM and IgD-expressing mature B 
cells. Activation with antigen results in differentiation into B lymphoblast cells, which 
proliferate polyclonally into high antibody-secreting plasma cells, and membrane bound 
Ig-expressing memory B cells. 
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Organization of the immunoglobulin heavy chain gene 
  
Regulation of the complexly organized IgH is carefully orchestrated by several 
regulatory regions located on both the 5’ and 3’ ends of the IgH gene. The most 5’ 
element of the IgH is the variable heavy chain promoter (VH) which is followed by VDJ 
regions which directly contribute to specificity of the immunoglobulin heavy chain 
during B cell development (Reviewed by Alt et al. 1992) (Fig. 2). The immunoglobulin 
heavy chain intronic enhancer (Eµ) is located 5’ to the  constant region and regulates 
VDJ joining during early B cell development (Serwe and Sablitzky, 1993) (Fig. 2). 
Initially, the E enhancer was believed to be the lone enhancer of the IgH. However, 
Serwe and Sablitzky (1993) conducted a study in which embryonic stem cells with a 
deleted E enhancer were used to produce chimeric mice that generated B cells that, in 
spite of the deleted E enhancer, still demonstrated V-DJ rearrangements of the IgH loci, 
although fewer rearrangements were observed than that of control B cells. This study was 
supported by additional studies in which IgH expression was maintained independent of 
the E enhancer (Wabl et al, 1984; Klein et al., 1984). Bottaro et al. (1998) supported 
evidence of a second enhancer region in studies in which hybridomas generated from 
cells containing a E deletion had significant but incomplete inhibition of CSR in the IgH 
locus, suggesting partial regulation by a separate regulatory region. Support for a second 
enhancer region was also established in studies in which CSR was disrupted by the 
deletion of an enhancer region located about 16 kb 3’ of the C gene in mouse B cells 
(Pattersson et al., 1990; Lieberson et al., 1991; Darizvach et al., 1991). We now know 
that enhancer as the hypersensitivity site 1,2 (hs1,2) enhancer. In another study, B cells 
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from hs1,2
 -/-
 chimeric mice displayed altered IgG isotype expression and a decrease in 
corresponding mRNA transcripts after LPS activation as compared to the wildtype mice, 
suggesting an altered CSR response (Cogné et al., 1994). Recent reports suggest that 
regulation of the IgH gene is partially mediated via physical interactions between the Eμ 
enhancer and the 3’IgHRR in plasma cells (Ju et al. 2007) and in primary splenic cells 
VDJ-3’IgHRR as well as E-3’IgHRR interactions were reported (Ju et al. 2007). 
Regulation of the 3’IgHRR is highly complex because it is composed of multiple distinct 
enhancers (Fig. 2), each containing binding sites for several transcription factors. The 
mouse 3’IgHRR contains four hypersensitivity sites associated with enhancer activity 
(hs3a; hs1,2; hs3b; and hs4) (Madisen and Groudine, 1994; Chauveau and Cogné, 1998; 
Saleque et al., 1997) (Fig. 2). Alternatively, the human IgH contains two 3’IgHRR 
downstream of two Cα regions, Cα1 and Cα2.  The two 3’IgHRR are nearly identical and 
contain three enhancers, hs3a, hs1,2 and hs4 with no equivalent of the mouse hs3b 
enhancer (Mills et al., 1997) (Fig. 2). The human C1 3’IgHRR demonstrates elevated 
transcription and expression versus the human C2 3’IgHRR (Mills et al., 1997). The 
difference could be due to a duplication event resulting in the inversion of the C2 hs1,2 
enhancer with respect to its Cα1 homologue (Mills et al. 1997). Additionally the 
difference in transcription and expression could be due to the fact that the E synergizes 
with the more upstream C1 3’IgHRR, increasing the overall enhancer strength (Mills et 
al., 1997). The discovery of the 3’IgHRR led to the question of the mechanism of 
chemically-induced deficiencies in B cell function, one specific chemical mediator being 
the potent contaminant TCDD.  
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Figure 2. Schematic of the mouse and human IgH genes. Variable heavy chain 
promoter, VH,, black oval; rearranged VDJ segments, red rectangles; E enhancer, blue 
circle; S regions, pink rectangles; constant regions, orange ovals, 3’IgHRR green boxes.       
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2,3,7,8-Tetrachlorodibenzo--dioxin (TCDD) 
2,3,7,8-Tetrachlordibenzo--dioxin (TCDD) is an environmentally persistent 
polycyclic aromatic hydrocarbon (PAH) (Fig. 3) that is produced as a byproduct in the 
combustion of chlorinated organic compounds (Reviewed by Fiedler, 1996 and  Fiedler 
et al., 2006). One common source of TCDD contamination is its release during the 
manufacture of commercial products (Reviewed by Fiedler, 1996; Fiedler et al., 2006). 
Additionally, TCDD is released as a pollutant from natural sources including forest fires 
and volcanoes (Reviewed by Fiedler, 1996; Fiedler et al., 2006). TCDD is a potential 
threat to human health due to bioaccumulation in humans and wildlife through multiple 
sources of exposure (i.e. air, drinking water, soil, dust and smoke) (Reviewed by Fiedler, 
1996; Fiedler et al., 2006). Research on the health effects of TCDD was spurred in the 
1970’s due its use in the infamous Agent Orange. Agent Orange was an herbicide that 
was sprayed to defoliate the dense terrain of trees, shrubbery, and crops of Vietnam in 
order to deny enemy cover and food during the Vietnam War (Kashida, et al., 2010). 
Agent Orange has been associated with prostate cancer, eczema, radiculopathy, diabetes 
mellitus, peripheral neuropathy, hypertension, and birth defects in exposed individuals 
(Giri et al., 2004; Kim et al., 2003a, 2003b; Ngo et al., 2006). Agent Orange consists of a 
mixture of 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid 
(2,4,5-T) with TCDD as a contaminant of the 2-4-5-T (Reviewed by Young et al., 2004). 
Aside from Agent Orange, TCDD has gained much media exposure ever since the 1970’s 
due to environmental disasters in which high amounts of TCDD were accidentally 
released (Fiedler et al., 2006). More recently TCDD made headlines in 2004 when it was 
used to poison Viktor Yushchenko, President of the Ukraine, which resulted in chloracne, 
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a disfiguring skin condition. The pathogenesis of chloracne includes a multitude of acne-
like eruptions of comedones, cysts and pustules, and by squamous metaplasia of 
epithelial cells within the duct of the sebaceous gland which may in part be due to 
constitutive activation of the TCDD/Aryl hydrocarbon receptor (AhR) pathway 
(described below) in epithelial cells (Geusau et al., 2001; Tang et al., 2008) (Fig. 3).  In 
addition, TCDD-associated hepatotoxic, carcinogenic, and immunotoxic effects have 
been reported in humans (Geusau et al., 2001). Furthermore, in laboratory animals, 
TCDD has produced hepatotoxic, immunotoxic, teratogenic, carcinogenic, and 
neurotoxic effects (Mandal 2005), in addition to a wasting syndrome and thymic atrophy 
(Poland and Knutson 1982). We have explored the immunotoxic effects of TCDD and 
found that when the mouse B cell line, CH12.LX, is activated by the polyclonal activator 
LPS, TCDD-co-treatment markedly inhibits IgM secretion (Sulentic et al., 1998, 2000). 
Moreover a decrease in IgM expression was also demonstrated in primary B cells that 
had been activated with LPS (Dooley and Holsapple, 1988) or anti-IgM (Karras and 
Holsapple, 1994) and treated with TCDD. Since Ig expression and secretion is regulated 
by the 3’IgHRR, we believe there could be a correlation between TCDD-induced 
immunotoxic effects and chemical modulation of the 3’IgHRR. The overall toxic 
response from TCDD, the most potent of the PAH family of chemicals, has been 
suggested to be due, in part, to its affinity for the aryl hydrocarbon receptor (AhR) and 
activation of the AhR pathway (Pohjanvirta et al., 1999). 
 
 
10 
 
A.  
 
B.  
 
 
Figure 3. Polyaromatic TCDD induces chloracne poisoning. A, polyaromatic 
hydrocarbon chemical structure of 2,3,7,8-tetrachlorodibenzo--dioxin 
(http://commons.wikimedia.org/wiki/File:Dioxine_pcdd.png). B, Viktor Yushchenko 
before (L) and after (R) 2004 TCDD poisoning that resulted in disfiguring chloracne 
lesions (http://blog.kievukraine.info/2007_07_01_archive.html). 
11 
 
TCDD, the aryl hydrocarbon receptor, and dioxin response elements  
 
The principle mechanism of TCDD toxicity is thought to be mediated through the 
AhR pathway. AhR studies were initially derived from research on the inducibility of the 
metabolic enzyme aryl hydrocarbon hydroxylase (AHH), which is also known as 
CYP1A1, of the cytochrome P450 superfamily of enzymes. Early AHH inducibility 
studies utilized mice that were able (responsive), or unable (non-responsive) to induce 
AHH and therefore metabolize PAH, benzo[a] pyrene (BP) or 3-methylcholanthrene (3-
MC) (Reviewed by Whitlock, 1990). However, when TCDD was established as a much 
more potent inducer of AHH than BP and 3-MC, ligand binding studies using [
3
H]-
TCDD in the responsive mouse strain were conducted to determine the receptor 
responsible for the induction. In these ligand binding studies an intracellular hepatic 
protein that could saturably bind TCDD with high affinity was discovered, and named the 
aryl hydrocarbon receptor (AhR) (Reviewed by Whitlock, 1990). The AhR has now been 
extensively characterized as a basic helix loop helix protein (bHLH) in the period/aryl 
hydrocarbon nuclear translocator protein/single minded (Per/ARNT/SIM) family. The 
Per/ARNT/SIM family of proteins is reportedly involved in regulation of genes 
controlling circadian rhythm, neurogenesis, stress response to hypoxia, and metabolism 
(Hogenesh et al., 1997; Hoffman et al., 1991; Crews et al., 1999; Liu et al., 2003). AhR 
has specifically been identified as a mediator of several cellular processes including 
regulation of cell cycle, inflammation, and metabolism of xenobiotics including, TCDD 
(Whitlock et al., 1999; Vogel et al., 2007; Singh et al., 2007; Ito et al., 2004; Bock and 
Khole et al., 2006). In addition to PAH environmental pollutants, the AhR is responsive 
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to halogenated hydrocarbons, and planar polychlorinated biphenyls, and recently, several 
naturally occurring dietary and endogenous ligands have been identified (Reviewed by 
Denison and Nagy, 2003). The AhR pathway has been extensively characterized using 
TCDD, the prototypic AhR ligand (Reviewed by Ma, 2001). Similar to the steroid 
signaling pathway, the AhR pathway begins when lipophilic TCDD crosses the cellular 
membrane. It binds to AhR, which is in a complex with two heat shock proteins (hsp90) 
and X-associated protein 2 (XAP2), and the co-chaperone protein p23 (Ma and 
Whitlock.1997; Carver et al., 1997; Perdew et al., 1991; Petrulis et al., 2003; Shetty et al., 
2003). The AhR complex of proteins and TCDD cross the nuclear membrane where AhR 
and TCDD dissociate from the protein complex and forms a heterodimer with the aryl 
hydrocarbon nuclear translocator (ARNT) which is also a bHLH protein (Hord and 
Perdew, 1994; Hoffman et al., 1991; Probst et al., 1993; Hankinson et al., 1995). The 
AhR/ARNT heterodimer is believed to induce transcriptional modulation by binding to 
dioxin response element (DRE) binding sites. Interestingly, AhR has been reported to 
bind DRE sites in the presence and absence of exogenous ligand (Ma et al., 1997). DRE 
binding sites consist of the core pentanucleotide sequence, GCGTG, and are well 
conserved throughout several mammalian genomes (Sun et al., 2004; Tijet et al., 2006). 
Several DRE sites have been identified in the enhancer region of the metabolic gene 
CYP1A1, the most studied target of TCDD (Whitlock et al., 1990; Masten and Shiverick, 
1995). Indeed, induction of CYP1A1 is the well established gold star indicator of a 
functional AhR pathway. In a study examining the role of the AhR in the effects of 
TCDD on IgM, the induction of CYP1A1 was compared to inhibition of IgM expression 
in activated CH12.LX cells. The findings indicated a structure activity relationship in the 
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induction of CYP1A1 and the inhibition of IgM expression and secretion in that higher 
affinity AhR ligands produced a greater effect on these endpoints (Sulentic et al., 2000). 
Furthermore, statistical analysis of concentration-response curves comparing IC50 values 
for  expression and IgM secretion to EC50 values of CYP1A1 induction were not 
significantly different further suggesting a common mechanism of action, i.e. the AhR 
pathway (Sulentic et al., 2000). Moreover, we identified DRE-like motifs in the hs1,2 and 
hs4 enhancers of the mouse 3’IgHRR (Sulentic et al., 2000) and EMSA-Western studies 
have confirmed binding of AhR nuclear protein from TCDD-treated CH12.LX cells to 
oligomers designed from the mouse hs1,2 and hs4 enhancer DRE sites (Sulentic et al., 
2000). Likewise, ChIP analysis confirmed AhR-DRE binding complexes in the hs4 
domain of the mouse 3’IgHRR (Sulentic et al., 2004a). Thus, we believe that TCDD may 
induce AhR/ARNT binding to DRE sites of the 3’IgHRR which, in turn, modulates 
transcriptional regulation of Ig expression and secretion.  
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Figure 4. The Aryl hydrocarbon pathway. TCDD enters the cell then binds with the 
AhR complex consisting of XAP2, p23, two HSP90 proteins. The complex translocates 
to the nucleus where the XAP2, p23, and HSP90 proteins dissociate from TCDD/AhR. 
The TCDD/AhR then forms a heterodimer with ARNT then binds to DRE sequences of 
the CYP1A1 gene and possibly the IgH gene which may modulate Ig expression and 
secretion. 
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Transcriptional modulation of the 3’IgHRR by TCDD 
In order to examine the effects of TCDD on transcriptional regulation of the 
3’IgHRR, we previously utilized luciferase reporter constructs containing the mouse 
variable heavy chain promoter and the mouse 3’IgHRR, hs4 or hs1,2 enhancers (Sulentic 
et al., 2004a, 2004b; Fernando et al., manuscript in preparation).  In these experiments we 
found that while TCDD and LPS co-treatment synergistically activate the hs4 enhancer, 
the activities of the mouse hs1,2 enhancer and the entire mouse 3’IgHRR were inhibited 
by TCDD in LPS-activated mouse CH12.LX cells (Sulentic 2004a, 2004b). In a separate 
study, a cell line was generated in which CRE-loxP technology was utilized to delete the 
hs3b and hs4 enhancers from a mini locus containing a 3’IgHRR-regulated g2b transgene, 
therefore, leaving the g2b transgene under the regulation of the hs3a and hs1,2 enhancers 
(Fernando et al., manuscript in preparation). This study demonstrated that while LPS 
activated g2b expression in the control cell line containing the complete 3’IgHRR-
regulated mini locus as well as the hs3a/hs1,2-regulated mini locus, the two mini loci 
were equally inhibited by TCDD which suggests that the TCDD-induced inhibition of the 
mouse 3’IgHRR in LPS-activated mouse B cells is mediated through the hs1,2 enhancer, 
(and possibly the hs3a enhancer) (Fernando et al., manuscript in preparation). 
Interestingly, whereas LPS-induced activation of the mouse hs1,2 enhancer is inhibited 
by TCDD, the human hs1,2 enhancer demonstrates synergistic activation in LPS-
activated and TCDD co-treated mouse CH12.LX cells (Fernando et al., manuscript in 
preparation). These studies clearly demonstrate the apparent difference between the 
effects of TCDD on the mouse versus human hs1,2 enhancers. Moreover, our previous 
studies suggest that each enhancer of the 3’IgHRR is individually regulated and support 
16 
 
the theory that multifaceted transcriptional regulatory events are contributing to the 
effects of TCDD on Ig expression and secretion in B cells.  
 
Basal transcriptional regulation of the individual enhancers of the mouse and 
human 3’IgHRR  
Over the last 20 years the basal transcriptional regulatory events of the 3’IgHRR 
have been outlined in human and mouse B cells. Indeed, several breakthrough studies 
have used the DNA fragmentation method in which restriction enzymes are utilized to 
map the individual enhancers of the mouse and human 3’IgHRR (Madisen and Groudine, 
1994; Chauveau et al., 1998; Mills et al., 1997; Kanda et al, 2000). In these studies 
transient and/or stable transfections were conducted using the enhancers of the 3’IgHRR 
cloned into reporter constructs of a promoter and the human growth hormone gene 
(Madisen and Groudine 1994), chloramphenicol acetyl transferase gene (Chauveau et al., 
1998), or a luciferase gene (Mills et al., 1997, Kanda et al., 2000). In each study an 
enhanserless reporter containing only the promoter was used as a negative control 
(Madisen and Groudine, 1994; Chauveau et al., 1998; Mills et al., 1997; Kanda et al., 
2000). The early studies established that the human and mouse hs1,2 enhancers were 
most transcriptionally active in late B cell lines such as mature B cells and 
plasmacytomas (Madisen and Groudine, 1994; Chauveau et al., 1998; Mills et al., 1997; 
Kanda et al., 2000). Moreover, the hs4 is the only enhancer that exhibited enhancer 
activity in pre and pro-B cells as well as in the later phases of B cell development 
(Madisen and Groudine, 1994; Chauveau et al., 1998; Giannini et al., 1993; Michaelson 
et al., 1996). Two studies utilizing human and mouse hs3 enhancers (hs3a and hs3b in 
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mouse studies) found that, alone, the hs3 enhancer had little or no activity (Chauveau et 
al., 1998; Mills et al., 1997). However, the hs3a and hs3b enhancers flanking the mouse 
hs1,2 enhancer were determined to be palindromes (Salaque et al., 1997) and a construct 
of the three mouse enhancers in tandem (hs3ahs1,2hs3b) generated the greatest 
activity in plasma cells compared to the individual enhancers (Chauveau et al., 1998). 
Furthermore, other studies agreed that, with respect to the individual enhancers, there was 
substantial activity when all of the enhancers were linked together in tandem in pre-B 
cells and mature B cells (Madisen and Groudine, 1994; Chauveau et al., 1998; Kanda et 
al., 2000). Moreover, a remarkable synergistic amplification was discovered when the E 
enhancer was added to constructs with all of the enhancers in tandem (Chauveau et al., 
1998). 
Several conserved transcription factor binding sites contribute to the basal activity 
of each individual enhancer region of the mouse and human 3’IgHRR. The mouse hs3a 
and hs3b enhancers are 97% identical and the mouse hs3a enhancer shares a 74% 
homology to the nearly identical human hs3 enhancers of the human C1 and C2 
3’IgHRR over a 200bp core segment (Mills et al., 1997; Chauveau and Cogné, 1996). 
The hs3 enhancers are the least studied of the 3’IgHRR due to their weak enhancer 
activity (Mills et al., 1997; Chauveau et al., 1998; Madisen and Groudine 1994), 
however, sequence analysis has indicated that the mouse hs3a and hs3b enhancers have 
AP-1 and Oct binding site (Mills et al., 1997, Madisen and Groudine 1994) and the 
human hs3 enhancers have conserved AP-1 and a SP1 motifs (Guglielmi et al., 2004; 
Mills et al., 1997). Interestingly, AP-1 binding proteins are activated by TCDD in mouse 
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hepa1c1c7 cells (Hoffer et al., 1996; Puga et al., 2000) and SP-1 binding has been shown 
to associate with NFκB proteins (Hirano et al., 1998). Similar to the hs3 mouse and 
human enhancers, the mouse and human hs4 enhancers share a 76% homology (Mills et 
al., 1997). The mouse and human hs4 enhancers have been reported as strong enhancers 
in early B-cell lineages, but also in some plasmacytoma cell lines (Kanda et al., 2000; 
Madisen and Groudine, 1994; Chauveau et al., 1998). Partially contributing to this 
enhancer activity is an exactly conserved Oct motif. Notably, the mouse hs4 enhancer has 
a weaker second Oct binding site (Guglielmi et al., 2004, Michaelson et al., 1996). Both 
of the Oct sites from the mouse hs4 have been confirmed by binding studies in pre-B and 
B cell lines (Michaelson et al., 1996). Additional contributors to mouse and human hs4 
activity include DRE and κB motifs (Sulentic et al., 2004a, 2004b; Mills et al., 1994; 
Guglielmi et al., 2004). The κB sites in the mouse and human hs4 enhancers have been 
established as necessities for hs4 enhancer activity (Kanda et al., 2000), and one of the 
κB sites on the mouse hs4 enhancer overlaps with a DRE site (Sulentic et al., 2000). 
EMSA-Western binding studies have demonstrated binding of AhR/ARNT and NFκB to 
this overlapping DRE and κB site (Sulentic et al., 2000). Additionally, ChIP assay has 
identified TCDD-inducible AhR binding, presumably to the DRE, in the hs4 enhancer in 
CH12.LX cells activated with LPS (Sulentic et al. 2004a). Further, site-directed mutation 
of the DRE and/or κB sites on an hs4 luciferase reporter construct demonstrated that the 
DRE and B cooperatively regulate the hs4 enhancer (Sulentic et al., 2004a, 2004b). 
Interestingly, Cos-7 cells demonstrated AhR-dependant modulation of NFκB binding 
activity in TCDD-treated cells and in the absence of AhR ligand (Tian et al., 1999). An 
additional characteristic of the mouse hs4 enhancer is the presence of a high affinity B 
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cell activator protein (BSAP) site (Mills et al., 1994), which was confirmed by EMSA 
binding studies with cold competitor (Michaelson et al. 1996). BSAP, also known as 
Pax5, negatively regulates early B-cell differentiation in part by repressing lineage-
inappropriate genes (Reviewed by Nutt et al., 2001, 2008). As B cells mature BSAP 
negative regulation maintains B cell identity (Reviewed by Nutt et al., 2008). However, 
expression of B lymphocyte-induced maturation protein 1 (BLIMP-1) in mature B cells 
inhibits BSAP repression in an autoregulatory negative feedback loop which results in 
terminal differentiation of B cells into plasma cells that do not express BSAP (Lin et al., 
2002; Mora-López et al., 2007; Delogu et al., 2006). Both the mouse and human hs4 and 
hs1,2 enhancers are complexly regulated via transcription factor binding to BSAP, κB, 
Oct, and possibly DRE sites in the various maturation stages of B cell development. In a 
pre-B cell line the κB and Oct sites are activators while the BSAP site is a repressor of 
the hs4 enhancer (Michaelson et al., 1996) (table 1). Further, the BSAP, κB, and Oct sites 
are concerted positive regulators of the mouse hs4 enhancer in a mature B cell line, and 
in plasma cells is a positive regulator of the hs4 and Oct has no effect on activity 
(Michaelson et al., 1996) (table 1). Conversely, in the mouse hs1,2 enhancer, BSAP, κB, 
and Oct sites exert a concerted repression in mature B cells (Michaelson et al., 1996, 
Singh and Birshtein 1996) (table 1). However, when the BSAP sites of the mouse hs1,2 
enhancers are mutated κB and Oct are no longer repressive in mature B cells (Michaelson 
et al., 1996; Singh and Birshtein, 1996) and in the absence of BSAP proteins, as is seen in 
plasma cells, NFκB and Oct proteins activate the hs1,2 enhancer (Michaelson et al., 
1996; Singh and Birshtein, 1996) (table 1). BSAP basal repression of the hs1,2 enhancer 
in the early B-cell lineages is consistent with findings that BSAP is an inhibitor of early 
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B-cell differentiation (Nutt et al., 1999). Additionally, the reduced BSAP expression in 
mature B cells to no expression in plasma cells (Reviewed by Nutt et al., 2001) could 
relate to the change from repression to activation by NFκB and Oct proteins. Notably, 
when mouse splenocytes and the mature B-cell line, CH12.LX, were co-treated with LPS 
and TCDD, they demonstrated prolonged expression of BSAP that was correlated with a 
decrease in IgH transcripts (Yoo et al., 2004; Schneider et al., 2008) which suggested that 
the maintained negative regulation from BSAP could have inhibited the change in role of 
Oct and NFκB proteins from repressive to activating factors. Furthermore, as stated 
above the κB and DRE sites of the hs4 enhancer have been found to cooperatively 
influence transcriptional regulation in TCDD-treated and LPS-activated B cells (Sulentic 
et 2004a, 2004b). Moreover, there is a possible κB site adjacent to a DRE sites of the 
hs1,2 enhancer which may also collectively influence transcriptional regulation of the 
hs1,2 enhancer. Thus, the DRE, κB, and Oct, in addition to the BSAP sites of the mouse 
hs1,2 enhancer could be contributing to the inhibitory effect of TCDD and LPS co-
treatment in mature B cells. Interestingly, the human hs1,2 enhancer, which shares a 90% 
homology over a 135 bp core sequence with the mouse enhancer, lacks a BSAP binding 
site (Mills et al., 1997), and is activated by LPS and TCDD co-treatment rather than 
inhibited as seen with the mouse hs1,2 enhancer. 
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Mouse hs4 enhancer BSAP  Oct 
Pre-B cell   
Mature B cell   
Plasma Cell   
    Mouse hs1,2 enhancer BSAP  Oct 
Mature B cell   
Plasma Cell   
  
Table 1. Regulation of the mouse hs4 and hs1,2 enhancers. Activation (), inhibition 
() or no change (-) in basal activity of the hs4 and hs1,2 enhancers of the 3’IgHRR by 
transcription factor binding to BSAP, κB, or Oct sites, as determined by site directed 
mutation or deletion results of studies in pre-B, mature B, or plasma cell lines. The hs1,2 
enhancer has low basal activity in pre-B cells which is the likely reason that it was not 
evaluated. BSAP has been reported to not be expressed in plasma cell lines, which is 
denoted by “*.” 
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Transcriptional regulation of the human hs1,2 enhancer 
Although, the mouse and human hs1,2 enhancers are highly homologous, the 
human hs1,2 enhancer has key sequence differences (figs. 5, 6) which may contribute to 
the TCDD-induced activation versus inhibition seen in the human versus mouse 
enhancers. Unlike the mouse hs1,2 enhancer, four alleles of the human hs1,2 enhancer 
have been identified, the 1A, 1B, 1C, and 2, each containing varying numbers of 
53bp tandem repeat (Denizot et al., 2001; Chen and Birshtein, 1997; Mills et al., 1997). 
The 1A (the wild type of the human allelic hs1,2 enhancer), 1B, and 1C alleles are 
polymorphisms of the C1 hs1,2 enhancer and contain one, two, and three repeats, 
respectively. The 2 allele is derived from the C2 hs1,2 enhancer and contains four 
53bp repeats (Mills et al. 1997; Denizot et al. 2001). Each 53bp repeat contains a DRE, 
NFκB, Ap-1, and two Sp-1 binding sites (Fig. 6) excluding the 1C allele which does not 
contain a third repeat of the complete NFκB and DRE binding sites (Denizot et al., 2001; 
Chen and Birshtein, 1997; Mills et al., 1997; Fernando et al., manuscript in preparation). 
Additionally, each repeat is flanked by an Oct site and an AP-1 site overlapping an Ets 
site (Denizot et al., 2001; Chen and Birshtein, 1997; Mills et al., 1997) (Fig. 6). 
Luciferase reporters consisting of the variable heavy chain (VH) promoter alone, or the 
VH promoter linked to the 1A, 1B, or 1C reporter, the human reporters demonstrated 
an increase in total activation by LPS in increasing order of 53bp repeats, however, 
excluding the 1C there was no difference in fold change relative to the basal activity 
(Fernando et al., manuscript in preparation). When the human hs1,2 enhancers were 
transfected into mouse CH12.LX cells and co-treated with LPS and TCDD, a synergistic 
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activation was observed, which also demonstrated an increase in activation according to 
number of repeats (Fernando et al., manuscript in preparation). Thus this activation 
appears to be related to the 53bp repeats and their associated transcription factor binding 
sites. Notably, the LPS and TCDD-induced fold-change of the 1C reporter is not 
increased to the extent of the 1A, possibly due to the lack of the DRE and NFκB 
binding sites in the third 53bp repeat, and the 1B had the greatest fold activation 
(Fernando et al., manuscript in preparation). Furthermore, the 1B reporter has been 
associated with several human autoimmune diseases including: IgA nephropathy (IgAN) 
(Aupetit et al., 2000), Celiac disease, systemic sclerosis, schizophrenia dermatitis 
herpetiformis, plaque psoriasis (Frezza et al., 2004, 2007, 2009), psoriatic arthritis 
(Cianci et al., 2008), and rheumatoid arthritis (Tolusso et al., 2009). These studies 
suggest a correlation with the 1B allele of the hs1,2 enhancer  and  immune 
deregulation of the IgA1 isotype (Aupetit et al., 2000), which could be related to altered 
regulation of the transcription factors in the 53bp repeat. Another recent study was 
conducted in which the DRE, NFκB, AP-1, and/or Oct binding sites were deleted from 
the 1A allele of the human hs1,2 enhancer in multiple combinations of deletions (DRE; 
B; DRE and B; Oct; DRE, B, AP-1; DRE,B, AP-1and Oct) (Fernando et al., 
manuscript in preparation). This study demonstrated that in TCDD and LPS co-treated 
mouse CH12.LX cells, the NFκB binding site was a positive regulator of the TCDD-
induced activation and the DRE was a slightly negative regulator (Fernando et al., 
manuscript in preparation). Additionally, the activation effect of TCDD was not 
completely abrogated until the deletion of the entire 53bp region (DRE, NFκB, AP-1) and 
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the Oct site in the flanking region (Fernando et al., manuscript in process). These results 
suggest that these sites of the 53bp and flanking regions may collectively contribute to 
the overall positive regulation of TCDD-induced activation of the human hs1,2 enhancer. 
However, these studies of the human hs1,2 enhancer were conducted in the mouse 
CH12.LX cell line. Since AhR endogenous expression and affinity to TCDD is species 
specific (Reviewed by Connor and Aylward, 2006), the true effect of TCDD on the 
human hs1,2 enhancer in a human B cell line is unknown. 
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Figure 5. Schematic of the mouse IgH locus and the mouse hs1,2 enhancer. The 
mouse IgH locus consisting of the VH, promoter, black oval; rearranged VDJ segments, 
red squares; E enhancer, blue circle; S regions, pink rectangles; constant regions, orange 
ovals, hs3a, hs3b, and hs4 enhancers, green rectangles and hs1,2 enhancer, red rectangle. 
Dotted lines point to an enlarged map of the hs1,2 enhancer depicting the relative 
location and sequence of the transcription factor binding sites of the mouse hs1,2 
enhancer. 
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Figure 6. Schematic of the human IgH locus and the C1 and C2 hs1,2 enhancer 
regions. The human IgH consisting of the VH,, black oval; rearranged VDJ segments, red 
squares; E enhancer, blue circle; S regions, pink squares; constant regions, orange ovals, 
hs3a, and hs4 enhancers, green rectangles and hs1,2 enhancer, red rectangle. Dotted lines 
point to an expanded depiction of the nearly identical C1 and C2 hs1,2 enhancers and 
the relative location and sequence of the transcription factor binding sites of the human 
hs1,2 enhancer. The bracket indicates the transcription factor binding sites included in the 
53 bp repeated polymorphism of the human hs1,2 enhancer.  
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The human IM-9 cellular model 
To date several studies have led us to enquire the effects of TCDD on the human 
hs1,2 enhancer in a human cell line. TCDD-induced effects mediated by the AhR have 
been extensively characterized in several cellular models including primary B cells 
(Crawford et al., 1997; Marcus et al., 1998). Also, numerous mouse and human cell 
studies have examined the 3’IgHRR. Further, the mouse CH12.LX B cell line has been 
utilized to study the inhibitory effect of TCDD on antibody secretion and Ig expression in 
LPS-activated cells (Sulentic et al., 1998, 2000). In addition, the TCDD-induced 
modulation of the mouse hs4 and hs1,2 enhancers and the 3’IgHRR in total has been 
examined in LPS-activated mouse CH12.LX cells (Sulentic et al., 2000, 2004a, 2004b). 
Moreover, we have recently completed several studies on the effects of TCDD on 
transcriptional regulation of the human hs1,2 enhancer in LPS-activated mouse CH12.LX 
cells (Fernando et al., manuscript in preparation). However, although  ligand-activated 
AhR has been characterized in human primary B cells (Allan and Sherr 2005), a gap 
remains in our understanding of the effects of TCDD on transcriptional regulation of the 
human hs1,2 enhancer, possibly through the AhR pathway, in a human B cell line. The 
human hs1,2 enhancer is of particular interest due to the association of the 1B allele 
with several human autoimmune diseases. In order to translate our mouse findings into 
relevant human application it is necessary to study the effects of TCDD on the human 
hs1,2 enhancer within a human B cell model. The IM-9 cell line is a potential model for 
such studies. The IM-9 cell line is reported by American Type Culture Collection to be a 
CD19
+
 human IgG secreting lymphoblastoid cell line. IgG secretion of the IM-9 cell line 
has been characterized by Fahey, Buell, and Sox (1971). Furthermore, Masten and 
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Shiverick (1996) demonstrated binding of nuclear protein from IM-9 cells to DRE 
oligomers which were supershifted with anti-AhR antibodies, suggesting functional AhR 
protein. Notably, the same group found that the BSAP sites of the CD19 gene and the 5’ 
S region of the g2a constant region on the IgH chain each have BSAP binding motifs 
which contain an embedded consensus region of the core DRE sequence (Masten and 
Shiverick, 1995). Utilizing EMSA analysis they demonstrated that binding of IM-9 
nuclear protein to a labeled oligomer consisting of a CYP1A1 DRE is partially inhibited 
by an unlabeled oligomer corresponding to the BSAP binding site of the CD19 gene, 
suggesting that AhR binds to the DRE embedded in the BSAP binding sites (Masten and 
Shiverick, 1995). Thus, the objective of this study was to 1) characterize the expression 
and function of the AhR in IM-9 cell line for use in mechanistic studies evaluating 
TCDD-induced effects on the human hs1,2 enhancer, 2) examine the effect of TCDD on 
the transcriptional regulation of the human hs1,2 enhancer in the human IM-9 cell line, 
and 3) determine if BSAP is mediating the divergence in transcriptional regulation 
between the mouse and human hs1,2 enhancers with TCDD treatment. 
 
Relevance 
Alteration in the regulation of the 3’IgHRR could pose a significant threat to human 
health since the AhR is activated by several environmentally persistent ligands, including 
TCDD, as well as a wide array of chemicals from environmental, dietary, and 
pharmaceutical origin. In fact, we have recently examined the inhibitory effects of several 
non-dioxin AhR ligands including, the dietary metabolite indolo(3,2,b)carbazole; the 
antimalarial drug primaquine; the pesticide carbaryl; and the proton pump inhibitor 
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omeprazole (Prilosec) on the expression of a stably transfected g2b transgene under the 
regulation of the mouse 3’IgHRR in LPS-activated mouse CH12.LX cells (Hensler et al., 
2009). Since modulation of the transcriptional activity of the hs1,2 enhancer has been 
associated with numerous autoimmune diseases, the elucidation of TCDD-induced 
effects, possibly mediated by the AhR, on the 3’IgHRR is highly relevant to human 
health. This study will be the first to examine the influence of TCDD on the human hs1,2 
enhancer in a human cell line model and should contribute to understanding the etiology 
of diseases related to the hs1,2 enhancer. Moreover, this study may elucidate the source 
of the divergence in transcriptional regulation seen between the human and mouse hs1,2 
enhancers which is highly significant because if major differences in regulation between 
human and mouse exist, these differences need to be taken into consideration when 
interpreting future toxicological and mechanistic studies specific to Ig expression using 
mouse models.   
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MATERIALS AND METHODS 
Chemicals and reagents 
TCDD in 100% DMSO was purchased from AccuStandard Inc. (New Haven, 
CT). Dimethyl sulfoxide (DMSO) and lipopolysaccharide (LPS, Escherichia coli) were 
purchased from Sigma Aldrich (St Louis, MO). CpG was purchased from the 
Macromolecular Structure, Sequencing and Synthesis Facility at Michigan State 
University (East Lansing, MI) and R848 was purchased from Alexis Biochemicals (San 
Diego, CA).  
 
Cell line models  
The IM-9 cell line was purchased from American Tissue and American Type 
Culture Collection (Rockville, MD). The IM-9 cell line is an Epstein-Bar Virus-
transformed B lymphoblastoid cell line which was isolated from a human Caucasian 
female patient with multiple myeloma. The IM-9 cell line was characterized by Fahey, 
Sox, and Buell (1971). IM-9 cells were grown in RPMI 1640 media (Mediatech, Inc., 
Manassas, VA) supplemented with 10% bovine calf serum (Hyclone Laboratories, 
Logan, UT), 10 mM HEPES, 20 mM sodium bicarbonate (Sigma Aldrich), 1 mM sodium 
pyruvate, 2 mM L-glutamine, 100 units/mL penicillin, 100 g/mL streptomycin (Fisher 
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Scientific, Hanover Park, IL), and 50 M 2-mercaptoethanol (Pierce, Rockford, IL). The 
CH12.LX cell line was generously donated by Geoffrey Haughton (University of North 
Carolina, Chapel Hill, NC). The source of the CH12.LX cell line was the murine CH12 
B-cell lymphoma, which was characterized by Bishop and Haughton (1996).  CH12.LX 
cells were grown under the same media conditions as the IM-9 cells except with 13.5 mM 
HEPES and 0.1 mM nonessential amino acids and no supplemental L-glutamine or 
sodium bicarbonate was added. All cells were maintained at 37 C in a 5% CO2 
atmosphere. 
 
Western blot 
 Preceding western blot analysis 50 mL of IM-9 cells in triplicate were left 
untreated or treated with vehicle (0.019% DMSO) or TCDD (30 nM) and incubated for 
24 hr at 37 C in a 5% CO2 atmosphere. Following incubation, the cells were centrifuged 
at 250 x g for 5 min at 4 C. The remaining pellet of cells was incubated for at least 1 h at 
-80 C with mild lysis buffer (NP-40, 1M NaCl, 0.1M NaPO4, 0.5M EDTA) containing 
freshly added Complete Mini protease inhibitor cocktail (Roche Applied Sciences, 
Indianapolis, IN) to lyse the cells. After samples were thawed on ice and cleared of debris 
by centrifugation, total protein per sample was determined using Bradford analysis (Bio-
Rad Laboratories, Hercules, CA). One hundred g of total protein per sample was then 
analyzed for the presence of the AhR by Western blot analysis. Briefly, cell lysates were 
resolved by electrophoreses with a denaturing 10% polyacrylamide SDS-PAGE (National 
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Diagnostics, Manville, NJ) in SDS electrophoresis running buffer (5 mM TRIS, 192 mM 
Glycine, 3.4 mM SDS) at 125V for 1.5 h. The proteins were transferred in 
Tris/borate/EDTA buffer (TBE) (890 mM Tris base, 890 mM boric acid, 0.5M EDTA) to 
a polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA). Membranes 
were then blocked overnight at 4C with 5% nonfat dairy milk (Kroger, Cincinnati, OH) 
and 0.05% Tween (Sigma) in TRIS buffered sailine. After blocking, the membrane was 
washed four times with 1x TBS for 5 min on a rocker plate (GyroTwister, Woodbridge, 
NJ). The membrane was incubated in a solution of 1:1000 primary antibody against the 
AhR (Abcam, Cambridge, MA), 3% bovine serum albumin (BSA) (Calbiochem, La Jolla, 
CA), and 0.05% Tween in TBS for 1 hr. The membrane was again washed four times for 
5 min each with 1x TBS on a rocker plate. A 1:5000 solution of goat anti-mouse 
secondary (Abcam) antibody conjugated with horseradish peroxidase, 3% BSA, and 
0.05% Tween in TBS was applied to the blot for 1 hr. The blot was rinsed 4 times for 
5min each with 1x TBS on a rocker plate. Supersignal western pico chemiluminescence 
substrate (ECL) (Thermo Scientific, Rockford, IL) was used to visualize the protein on a 
Fuji Las 3000 imager (FujiFilm Corporation, Tokyo, Japan). 
 
RNA isolation  
 CYP1A1 RNA transcripts were amplified by RT-PCR. Briefly, 1mL of IM-9 
cells, in triplicate, were left untreated or treated with vehicle (0.019% DMSO) or TCDD 
(30nM) then incubated for 24h at 37C in a 5% CO2 atmosphere. Following the 
incubation period, samples were centrifuged at 2000 rpm and pellets were re-suspended 
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in 100L of Tri-Reagent (Sigma Life Science, St Louis, MO) then stored at -80C. 
Samples were thawed at room temperature then centrifuged at 12,000 x g for 10min. The 
aqueous layer was removed and mixed with 10 L BCP (Sigma-Aldrich) then loaded into 
Phase Lock Gel tubes (5PRIME, Gaithersburg, MD) and vortexed. Tubes were incubated 
for 10min at room temperature then centrifuged at 12,000 x g and 4C for 5min to clear 
the Tri reagent phenol from the samples. The clear aqueous layer was removed and 
combined with 100L isopropanol (Pharmco-Aaper and Commercial Alcohols, 
Brookfield CT) and incubated for 10min at room temperature. Samples were centrifuged 
for 8min at 12,000 x g at 4C then pellets were washed with 75% ethanol (ACROS 
Organics, Geel, Belgium). Pellets were dried for 15min then re-suspended in 25L of 
distilled water and dissolved by rocking motion for 30 min then stored at -80C. 
 
Reverse Transcriptase and Real-time Polymerase Chain Reaction (RT-PCR) 
 RNA isolated above was reverse transcribed into cDNA using RT-PCR. RNA 
samples were measured for total RNA using the NanoDrop (NanoDrop Technologies, 
Wilmington, DE). Each sample was normalized to a concentration of 1g/19.25L. A 
master mix solution was made using the Taqman RT-PCR kit (Applied Biosystems, 
Branchburg, NJ). Briefly, 19.25L of RNA sample combined with 5L Taqman RT 
buffer, 11L 25mM MgCl2, 10L dNTPs, 2.5 random hexamers, 1L RNAse inhibitor, 
and 1.25L Reverse Transcriptase were reverse transcribed using a Thermo cycler 
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(Eppendorf, Hauppauge, NY)  for 25C for 10min, 48C for 30min, 95C for 5min, then 
a 4C hold. The resultant cDNA samples were then stored at -80C.    
  Amplification of Cyp1a1 transcripts from the cDNA above was measured by 
Real Time Polymerase Chain Reaction. Briefly, Cyp1a1 and B-actin primers were 
generated using Primer3 Software ((http://fokker.wi.mit.edu/primer3/input.htm). Ten 
pmol of forward and reverse Cyp1a1 primers (FP: CCTCTTTGGAGCTGGGTTTG; 
RP:GCTGTGGGGGATGGTGAA)  and 2.5L of 1:10 diluted DNA, were added to 2x 
SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK).  Then, SYBR 
Green incorporation was measured for 40 cycles by the 7500 real-time PCR system 
(Applied Biosystems, Warrington, UK). Amplified transcripts of -actin, a housekeeping 
gene (FP:TCACCCACACTGGGCCCATCTACGA; 
RP;CAGCGGAACCGCTCATTGCCATGG) were measured in a separate tube  as a 
positive control. Fold induction was measured relative to the vehicle samples.  
 
Enzyme Linked Immunosorbent Assay (ELISA) 
IM-9 cells were grown to stationary phase (1.2 - 1.4 x 10
6
 C/mL) then cut back to 
log phase, 6.0 x 10
4
 – 5.0 x 10
5
 C/mL, based on total treatment time. One milliliter 
samples of IM-9 cells, in triplicate, were left untreated or treated with vehicle (0.019% 
DMSO), R848 (0, 10, 100, or 1000 nM), CpG (0.1, 0.5, 1, 3, 5, or 6 M) or TCDD 
(30nM) then incubated at 37C in a 5% CO2 atmosphere for 4 – 96 hr. Twenty microliters 
of each sample was then diluted 1:1 with Trypan Blue (Beckman Coulter, Brea, 
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California) and counted by hemocytometer (AO Scientific Instruments, Buffalo, NY). 
The remaining samples were centrifuged at 250 x g and pellets were re-suspended in 50 
L mild lysis buffer containing complete mini (protease inhibitor). Supernatants were 
analyzed by sandwich ELISA for IgG, as previously described (Sulentic et al., 1998). 
Briefly, 100L of supernatant or IgG standard (human, Bethyl Laboratories, 
Montgomery, TX) was loaded to a 96-well plate coated with 1:2500 goat-anti-human 
capture antibody (Southern Biotech, Birmingham, AL), diluted in 0.1% sodium 
bicarbonate then incubated for 1.5 hr. Following the incubation period, the plate was 
washed 3x with 0.05% Tween in phosphate buffered saline (PBS) and 4x H2O by a plate 
washer. Horseradish peroxidase anti-human capture antibody (Bethyl Laboratories) 
diluted 1:10000 in a solution of 3% BSA, 0.05% Tween, and PBS was loaded to the plate 
and incubated for 1.5 hr. Excess antibody was washed 3x with 0.05% Tween in PBS and 
4x with H2O by a plate washer. Colorimetric detection of IgG captured on the plate was 
performed by adding 100 L of ABTS substrate (2,29-azinobis(3-ethylbenz thiazoline-
sulfonic acid)) (Roche Diagnostics, Indiana, IN) and measuring the absorbance using the 
kinetic mode (1 min intervals for 60 min) using a Spectramax plus 384 automated 
microplate reader with a 405 nm filter (Molecular Devices, Sunnyvale, CA). The 
concentration of IgG in each sample was calculated from a standard curve of known 
concentrations of human IgG using the SOFTmax PRO analysis software (Molecular 
Devices). 
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Reporter plasmids 
Human luciferase reporters were kindly provided by Dr. Michel Cogné, 
(Laboratoire d’Immunologic, Limoges, France). The reporters consisted of an 
enhancerless variable heavy chain promoter (VH) 5’ to the luciferase gene or the VH 
promoter and the luciferase gene upstream of the human polymorphic hs1,2 enhancer 
consisting of either one (α1A), two (α1B), or three (α1C) 53bp repeats, as described 
previously (Denizot et al. 2001) (Fig. 7). All plasmids were constructed using a pGL3 
basic luciferase reporter construct, (Promega, Madison, WI). A BSAP binding site added 
to the 1A human hs1,2 enhancer reporter (1A+BSAP) was previously prepared by our 
laboratory using site-directed mutagenesis according to QuikChange XL Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA). Oligonucleotide primers were designed to 
add a BSAP binding motif (TS- GTGGTCCCAGTGTCAGCCCTGGGGTGTTGAGCC- 
ACCCATCCTTGCCCTAACCCAAGTGGGCCT; BS-AAGCCCACTTGGGTTAGGG- 
CAAGGATGGGTGGCTCAACACCCCAGGGCTGACACTGGGACCAC) using the 
QuikChange Primer Design Program (http://www.stratagene.com/ sdmdesigner).  Briefly, 
10 ng of the 1A human hs1,2 reporter was combined with 5 μL 10x reaction buffer, 125 
ng of each oligonucleotide primer, 1 μL of dNTP mix, 3 μL of QuikSolution, and 1 μL of 
PfuTurbo DNA polymerase to a final volume of 50 L in thin-walled PCR tubes. 
Samples were heated to 95 C for 1 min then cycled 18 times, at 95 C for 50 s, 60 C for 
50 s, and 68 C for 6 min per cycle (1 min/kb). A 7 min final extension step occurred at 
68 C after 18 cycles. Next, the parental DNA template was digested with Dpn I. The 
remaining DNA plasmid was transformed into XL10-Gold Ultracompetent cells, then 
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isolated and the desired addition validated by sequencing (Retrogen, Inc., San Diego, 
CA). 
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Figure 7. Human hs1,2 enhancer luciferase reporter constructs. Each reporter 
plasmid was made using a pGL3 basic luciferase construct and contained a variable 
heavy chain (VH) promoter. The number of 53bp repeats in each allele of the 
polymorphic human hs1,2 enhancer is denoted by  asterisk “*.”   
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Transient transfections 
IM-9 cells were grown up to their stationary phase concentration (1.2 - 1.4 x 10
6
 
C/mL) then 1.0 x 10
7 
C were suspended in 200 L of culture media with 10 g of 
reporter and transferred to a 2 mm gap electroporation cuvette (Molecular Bioproducts, 
San Diego, CA). Cells were electroporated using an electro cell manipulator (ECM 630, 
BTX, San Diego, CA) at a voltage, capacitance, and resistance of 150 V, 1700 F, and 75 
Ω, respectively. Multiple transfections per plasmid were pooled and divided into 
treatment groups at a concentration of 1 x 10
6 
C/mL. CH12.LX cells were grown up to 
log phase (5 x 10
5 
C/mL) then 1.0 x 10
7
C were electroporated as described above at a 
voltage, capacitance, and resistance of 250 V, 150 F, and 75 Ω, respectively. Multiple 
transfections per plasmid were pooled and divided into treatment groups at a 
concentration of 5 x 10
5 
C/mL. Immediately following transfection, unstimulated IM-9 
cells were treated with vehicle (0.019% or 0.1% DMSO) or TCDD, or were co-treated 
with TCDD and CpG and/or R848. Unstimulated or LPS-stimulated CH12.LX cells were 
treated with (0.019% DMSO) or TCDD (30nM), or were co-treated with TCDD and LPS. 
Treated IM-9 and CH12.LX cells were aliquoted in triplicate into 12-well plates for a 24h 
incubation period. Cells were then lysed with 1x reporter lysis buffer (Promega) and 
frozen at 80C for at least 1 hr. 
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Luciferase Assay 
 To measure luciferase activity, samples were thawed on ice, centrifuged at 14,000 
rpm for 5 min. Then twenty microliters of sample supernatant was added to 100L 
luciferase assay reagent (Promega). Luciferase activity (i.e. luminescence) was measured 
using a Sirius luminometer (Berthold Detection Systems, Oak Ridge, TN) and was 
represented as relative light units. 
  Traditionally transfection efficiency is determined by co-transfecting a control 
plasmid such as -gal. However, common stimulants, such as LPS reportedly activate the 
promoter and enhancers of control plasmids, making precise standardization of the 
activity of the control plasmid difficult to determine. Therefore, transfection efficiency 
was measured by quantitative real-time PCR. DNA was isolated from naïve samples that 
had been incubated for 2h following transfection using the GenElute Mammalian 
Genomic DNA miniprep kit (Sigma-Aldrich). Purified DNA was diluted 10-fold and then 
analyzed by real-time PCR for the luciferase gene. Briefly, primers specific for the 
luciferase gene encoded with the pGL3 luciferase vector series, were previously 
generated by our laboratory using Primer3 Software. Next, 10pmol of forward and 
reverse primers and 2L of diluted purified DNA, were added to 1x SYBR Green PCR 
Master Mix (Applied Biosystems). Then, SYBR Green incorporation was measured for 
40 cycles by the 7500 real time PCR system (Applied Biosystems). A standard curve of 
known quantities of plasmid DNA was utilized to measure the concentration of plasmid 
DNA. The total amount of plasmid (ng of plasmid) was calculated by multiplying the 
concentration of plasmid DNA (ng of plasmid/L), the volume of DNA added (2 L), 
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and the fold dilution (10). The plasmid number per cell was calculated using the 
following equation: [(nanograms of plasmid) x (molecules of plasmid / nanograms of 
plasmid )/ cell number], as previously described (Sulentic et al., 2004).  
 
Statistical Analysis of Data 
 The mean ± SE (n=3) was calculated for each treatment group within each 
experiment. Significance between treatment groups of real-time PCR studies was 
determined by a 1-way ANOVA followed by a Dunnett’s two-tailed t test. Significance 
between treatment groups and time points in ELISA studies was determined by 2-way 
ANOVA followed by a Bonferroni’s two-tailed t test. In luciferase assays, significance 
between treatment groups of 1 plasmid was determined by 1-way ANOVA followed by a 
Dunnett’s two-tailed t test. Significance between multiple plasmids was determined by 2-
way ANOVA followed by a Bonferroni’s two-tailed t test. TCDD-induced fold activation 
in luciferase studies was calculated by dividing the mean luciferase activity of TCDD 
and/or stimulant-treated samples by the mean luciferase activity of the appropriate 
vehicle. Mean fold change for TCDD activation ± SE was determined by analyzing 
eleven separate experiments. Luciferase activity relative to transfection efficiency was 
calculated by dividing the mean plasmid number of the VH reporter by the mean plasmid 
number of the appropriate hs1,2 reporter. The quotient was then multiplied to the 
luciferase activity results for each treatment group for the appropriate hs1,2 reporter.  
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RESULTS 
Characterization of IM-9 cells 
Our lab has utilized the mouse CH12.LX cell line extensively to study the role of 
the AhR/DRE in the inhibitory effect of TCDD on antibody secretion and Ig expression 
(Sulentic et al., 1998; Sulentic et al., 2000) as well as the TCDD-induced inhibition of 
3’IgHRR activation (Sulentic et al., 2004a; Sulentic et al., 2004b). In order to translate 
our mouse findings into relevant human application it is necessary to utilize a human B-
cell line model in which to study the effects of TCDD on the human 3’IgHRR. We 
decided to characterize the human lymphoblastoid IM-9 cell line as a model for TCDD 
toxicology studies because: 1) it demonstrated TCDD-induced binding of the AhR to an 
oligomer containing a DRE site from the Cyp1a1 gene (Masten and Shiverick, 1996), a 
metabolic gene of which expression is a hallmark of a functional AhR pathway; 2) our 
preliminary EMSA analysis demonstrated TCDD-induced binding of the AhR from IM-9 
cells to an oligomer containing the DRE-like site from the human hs1,2 enhancer, also 
suggesting a functional AhR pathway (data not shown); 3) we successfully transiently 
expressed a luciferase reporter regulated by the human hs1,2 enhancer in IM-9 cells, 
which supported the use of IM-9 cells in studies of transcriptional activation of the 
human hs1,2 enhancer. Collectively, our preliminary results supported the 
characterization of the IM-9 cell line for the use as a model for determining the molecular 
mechanisms behind TCDD-induced modulation of the 3’IgHRR.  
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IM-9 cells express the AhR:  The expression of a functional AhR is a necessity for our 
studies, as the mechanism for TCDD-induced effects is thought to be mediated by the 
AhR. By Western blot analysis we confirmed AhR expression in unstimulated IM-9 
whole cell lysates (Fig. 8). Since unstimulated human primary B cells were reported to 
have low expression of AhR (Allan and Sherr, 2005), we loaded 100 g of IM-9 protein 
versus 50g of CH12.LX protein. Accordingly, our results confirmed the expression of 
AhR in IM-9 cells. Interestingly, although twice as much total protein from IM-9 cells 
versus CH12.LX cells was loaded to the blot, the levels of AhR expression from the two 
cell lines appeared to be similar. Notably, whereas the size of mouse AhR has been 
reported to be 96 kDa, human AhR has been reported to be 110 kDa, which corresponds 
with our results. In previous studies cellular activation resulted in an increase in AhR and 
CYP1A1 expression in mouse primary splenocytes and isolated primary B cells 
(Crawford et al., 1997; Marcus et al., 1998). In addition, activated mouse primary B cells 
treated with TCDD demonstrated an increase in AhR binding to a DRE oligomer versus 
cells that were not activated in EMSA/Western studies (Crawford et al., 1997). These 
results suggest that increased AhR expression due to activation of mouse primary B cells 
may result in an increase in B cell sensitivity to TCDD and activation of the AhR 
pathway. In our previous experiments, we activated AhR expression in mouse CH12.LX 
cells with LPS, a toll-like receptor 4 (TLR4) ligand and B-cell stimulant (Sulentic et al., 
1998). However, it has been reported that while LPS is not an efficient activator of 
human B cells, CpG, a TLR9 stimulant, effectively activates human B cells (Bauer et al., 
2001). Likewise Allan and Sherr (2005) found an upregulation of AhR expression and 
ligand-independent activation in CpG-activated primary human B-cells. Thus, we 
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attempted to upregulate AhR expression by activating the IM-9 cells with CpG. We 
found that only 24 h of CpG treatment may have slightly activated the AhR in IM-9 cells. 
However, expression of the AhR in IM-9 cells was not appreciably upregulated as a 
result of CpG treatment (Fig. 8), which suggests that CpG may not be an effective 
activator of IM-9 cells, particularly based on later studies demonstrating a lack of IM-9 
activation with CpG (see below). Nonetheless, upregulation AhR was not a necessity for 
our studies, as the basal expression of AhR was clearly demonstrated, warranting further 
characterization of the IM-9 cell line (Fig. 8) 
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Figure 8. CpG treatment does not appreciably increase AhR expression in human 
IM-9 cells. Whole cell lysate (100 µg) from naïve (Na) IM-9 cells (5x10
5 
C/mL) or cells 
treated with CpG (1 µM) for 24, 48, or 72 h was loaded into lanes 2-7, resolved on a 10% 
SDS-PAGE gel, and probed with mouse anti-AhR antibody (0.1 µg/mL). Lysate (50 µg) 
from naïve CH12.LX cells (5x10
5 
C/mL) was loaded into lane 1 as a positive control. 
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IM-9 cells have a functional AhR signaling pathway: Since TCDD-induced effects are 
thought to be mediated through the AhR pathway, a functional AhR pathway in IM-9 
cells is essential for our mechanistic studies. As stated above, several past mechanistic 
studies have established induction of the CYP1A1 gene, a metabolic gene, as the 
hallmark of a functional AhR pathway (see Ma, 2001 for review). Therefore, we chose to 
utilize real-time RT-PCR to quantify RNA transcripts for the CYP1A1 gene in naïve or 
TCDD-treated IM-9 cells. We found a marked induction of CYP1A1 in the TCDD-
treated cells which suggest that IM-9 cells have a functional AhR pathway (Fig. 9). 
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Figure 9. TCDD induces CYP1A1 induction. Reverse transcribed cDNA from 
untreated IM-9 cells or cells treated for 24h with vehicle (0.019% DMSO) or 30 nM 
TCDD was amplified by real-time PCR with -actin as an internal control. Fold induction 
was relative to NA.   
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IM-9 cells express basal IgG: Previous experiments in our laboratory support the theory 
that TCDD inhibits antibody secretion through the AhR pathway in the mouse CH12.LX 
cell line (Sulentic et al., 1998; Sulentic et al., 2000). Therefore, we hypothesize that 
modulation of Ig secretion is a toxicological endpoint of TCDD induction of the AhR 
pathway in a human cell line. In order to determine if IM-9 cells are a viable model for 
studying the TCDD-induced effects on Ig secretion, we chose to characterize basal Ig 
secretion in IM-9 cells. Importantly, a prerequisite for determining antibody secretion 
was to develop the most effective culturing conditions for the IM-9 cell line by analyzing 
proliferation patterns corresponding with basal Ig secretion. A complex proliferation and 
basal Ig secretion pattern in the IM-9 cell line was reported by Fahey, Buell and Sox 
(1971). Since cell lines are known to change their phenotype over time, likely due to 
various reasons including different culturing practices, our studies focused first on 
verifying optimum culturing conditions for activation of Ig expression. In correlation 
with the Fahey, 1971 study, we found that in order to see significant basal IgG secretion, 
IM-9 cells had to be grown up to a stationary growth phase (cell concentration  1.2 x 10
6
 
C/mL) then reduced in concentration to obtain a log growth phase (cell concentration 
between 2.5 x 10
4
 and 5.0 x 10
5
 C/mL). Then this cycle of concentration growth and 
reduction was to be repeated once. After the second reduction in concentration to obtain a 
log growth phase, basal Ig was expressed and could be sampled as cells proliferated back 
up to a stationary phase. Using these culturing practices we established that the current 
IM-9 cell line secretes IgG, however, when normalized to cell number, naïve IM-9 cell 
supernatant only demonstrated low levels of secreted IgG in the magnitude of ng per 10
5
 
cells (Fig. 10), whereas the levels of secreted IgG seen in the Fahey study (1971) was in 
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the magnitude of hundreds of ng per 10
5 
cells. Differences in magnitude of basal IgG 
secretion suggest that the IM-9 cell line may have changed in phenotype or our particular 
culturing conditions, such as the type and lot of serum, may influence the basal IgG 
levels. Interestingly, physiological levels of human IgG are g per liter in magnitude. 
Thus, our levels of IgG secretion in the human IM-9 cell line may not be physiologically 
significant.  
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Figure 10. Basal IgG secretion from IM-9 cells normalized to cell number. IM-9 cells 
were allowed to grow to a stationary concentration (cell concentration  1.2 x 10
6
 C/mL) 
then reduced in concentration to a log concentration (cell concentration between 2.5 x 10
4
 
and 5.0 x 10
5
 C/mL) (data not shown). Then cells were again grown to a stationary phase 
(1.5 x 10
6
 C/mL) then reduced in concentration to a log phase (5.0 x 10
5
 C/mL). A, the 
first cell concentration was measured by hemocytometer during the second stationary 
phase just prior to the second concentration reduction to 5 x 10
5
 C/mL (-4 h). Then, 
following a 4 h recovery period, samples were collected and cell concentration was 
measured in 12 h intervals for 96 h. B, secreted IgG concentration was measured by 
ELISA.  
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IgG expression in IM-9 cells is not significantly activated by CpG or R848: We 
previously demonstrated in mouse CH12.LX cells that IgM expression activated by LPS-
stimulation was inhibited by TCDD (Sulentic et al., 1998). Since in CH12.LX cells 
TCDD-induced inhibition of Ig required cellular activation we attempted to identify a B-
cell activator for our human IM-9 cells. As previously stated, CpG has been shown to 
activate human B cells (Bauer et al., 2001). In our earlier studies we found that CpG did 
not appreciably stimulate upregulation of the AhR. However, there was still the 
possibility that CpG would stimulate IgG expression. Thus, we tested CpG as a stimulant 
of IgG expression in IM-9 cells and found a modest activation of IgG at 36 h by 0.5 M 
CpG (Fig. 11), however higher concentrations (1 and 3 M) of CpG significantly 
inhibited background IgG expression (fig 11). Given that the CpG activation we saw was 
not significant, we considered testing R848 as a stimulant. R848 has been reported as a 
TLR7 agonist that mimics CD40L activation (Bishop et al., 2001). CD40L is primarily 
expressed on activated T cells and was demonstrated by Allan and Sherr (2005), to be a 
promising but expensive stimulant of primary human B cells. Thus, we attempted to 
stimulate IM-9 cells with R848, an affordable substitute to recombinant CD40L. We 
found little or no significant activation in IgG concentration relative to vehicle control 
(0.1% DMSO) in IM-9 cells treated with 10-1000 ng/mL R848 for 36-96 h. However, our 
24 h samples showed variably showed no effect or inhibition in IM-9 cells treated with 
100 ng/mL R848 (p<0.05). (Fig. 12). Although, IM-9 cells have been reported to be high 
IgG-secreting lymphoblast (Fahey et al., 1971), we did not detect high basal IgG 
secretion and have yet to find an optimal stimulant for these cells. The appropriate 
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activation stimuli may be more complex and involve a combination of stimuli including 
interleukins and CD40L.    
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Figure 11. A low concentration of CpG modestly activates IgG secretion in IM-9 
cells. IM-9 cells were allowed to grow to a stationary phase concentration (cell 
concentration  1.2 x 10
6
 C/mL) then reduced in concentration to a log phase 
concentration (cell concentration between 2.5 x 10
4
 and 5.0 x 10
5
 C/mL) (data not 
shown). Cells were then again grown to a stationary phase concentration and then 
reduced in concentration to 5.0 x 10
5
 C/mL. Naïve (NA) IM-9 cells and cells treated with 
0.5, 1 or 3M CpG were incubated for 24-48h. A, samples were collected and cell 
concentration was measured by hemocytometer at 24, 36, and 48 h. B, IgG concentration 
was measured by ELISA. Two-way ANOVA followed by a Bonferroni’s two-tailed t test 
(95% confidence interval) indicates significant inhibition relative to the NA control at a 
concentration of 1 M CpG (*) (p<0.05), and 3 M CpG (***) (p<0.001).  
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Figure 12. IM-9 cells are not activated by R848. IM-9 cells were allowed to grow to a 
stationary phase concentration (cell concentration  1.2 x 10
6
 C/mL) then reduced in 
concentration to a log phase concentration (cell concentration between 2.5 x 10
4
 and 5.0 x 
10
5
 C/mL) (data not shown). Then, untreated IM-9 cells were again grown to a stationary 
phase and then reduced in concentration to 3.5 x 10
4
 C/mL. Naïve (NA) IM-9 and cells 
and cells treated with 0.1% DMSO vehicle, 10, 100, or 1000 ng/mL R848 were incubated 
for 24-96h. A, Samples were collected and cell concentration was measured by 
hemocytometer at 24, 36, 48, 72 and 96 h. B, IgG concentration was measured by 
ELISA. Two-way ANOVA followed by a Bonferroni’s two-tailed t test (95% confidence 
interval) indicated significant differences compared to the vehicle control p<0.05 (*), 
p<0.01 (**). 
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Transfection of the polymorphic human hs1,2 enhancer into IM-9 cells 
 
Our lab has demonstrated that TCDD induces binding of the mouse AhR to a 
DRE site within an oligomer from the hs1,2 enhancer region of the 3’IgHRR (Sulentic et 
al., 2000). We have also shown that TCDD inhibits transcriptional activity of the mouse 
hs1,2 enhancer (Fernando et al. manuscript in preparation), which suggests that 
regulation of the mouse hs1,2 enhancer may be a sensitive transcriptional target of TCDD 
through the AhR signaling pathway. Since the mouse and human hs1,2 enhancers share a 
90% core sequence identity (Mills et al. 1997), we propose that the transcriptional 
regulation of the human hs1,2 enhancer may also be a sensitive transcriptional target of 
the human AhR pathway. Three allelic polymorphisms of the human hs1,2 enhancer have 
been reported, α1A, α1B, and α1C, each containing a 1, 2, or 3-53 bp tandem repeats, 
respectively (Denizot et al., 2001). We previously found that activation of luciferase 
reporters consisting of the VH promoter and the  or the 1C allele of the hs1,2 
enhancer was TCDD concentration-dependent, and cells stimulated with LPS and co-
treated with TCDD demonstrated an enhanced activation that was dependent on number 
of 53 bp repeats in addition to being TCDD and LPS concentration-dependent (Fernando 
et al., manuscript in preparation). Strikingly, however, the 1B reporter, the allele that 
has been associated with several human autoimmune diseases, showed the greatest fold-
activation (p<0.05) of the three hs1,2 reporters in LPS-activated and TCDD co-treated 
CH12.LX cells (Fernando et al., manuscript in preparation), Still, a gap remained in our 
understanding of the effects of TCDD on transcriptional regulation of the human hs1,2 
enhancers in a human cell line. In preliminary experiments we found, in correspondence 
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with studies in the mouse CH12.LX cell line, the 1B wild type reporter, transfected into 
human IM-9 cells demonstrated a TCDD-induced increase in activity. However, the 
effect of TCDD on the 1A and 1C alleles of the hs1,2 enhancer in human cells had not 
been determined. Accordingly, we conducted transfection studies on all three of the 
human hs1,2 reporters to evaluate the effects of TCDD in the human IM-9 cell line 
 
Culturing conditions for transfection studies in IM-9 cells: In the above mentioned Ig 
experiments we determined that IM-9 cells required a complex culturing pattern in order 
to express Ig. Therefore, to determine ideal culturing conditions, we conducted several 
studies in which the IM-9 cells were initially grown to lag, log, or stationary phase, 
transfected with the 1B reporter, then seeded at lag, log, or stationary phase and treated 
with TCDD. In addition, previous studies have demonstrated that human AhR has a 
lower level of endogenous expression and affinity for TCDD than mouse AhR (Harper et 
al., 1988). Furthermore, we found lower expression of human AhR versus mouse AhR in 
IM-9 and CH12.LX cells, respectively in our earlier Western Blot studies. Therefore, we 
initially tested both a standard concentration (30nM, for our laboratory) and a high 
concentration (100 nM) of TCDD in our culturing condition studies because low AhR 
expression may be associated with lowered sensitivity to TCDD, as has been suggested in 
other studies (Harper et al., 1998; Ema et al., 1994). We found a significant TCDD-
induced activation in the log-stationary (i.e., grown to log phase then transfected and 
reseeded at a stationary phase concentration), and stationary-stationary (i.e., grown to 
stationary phase then transfected and reseeded at a stationary phase concentration) culture 
conditions with both 30nM and 100nM concentrations of TCDD (Fig. 13). Interestingly, 
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there was a marked increase in overall luciferase activity levels of the log-stationary 
samples versus the stationary-stationary samples (Fig. 13). In spite of this, we saw 
slightly higher TCDD-induced fold-activation in stationary-stationary samples versus 
log-stationary samples treated with 30 nM TCDD (fig 14). When we compared these 
results to a pilot study in which we treated the 1C reporter with 30 nM TCDD, we saw a 
similar trend in fold-activation (fig 14). Consequently, we decided to use stationary-
stationary culturing conditions in our transfection studies. We decided to use 30 nM 
TCDD versus 100 nM TCDD because 30 nM TCDD is closer to common TCDD 
exposure levels than the 100 nM TCDD and results from additional studies did not show 
a great difference in fold induction from 30 nM TCDD versus 100 nM TCDD. This 
corresponds to studies in mouse CH112.LX cells in which TCDD-induced fold-activation 
seemed to plateau at 30 nM TCDD (Fernando et al., manuscript in preparation).  
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Figure 13. The 1B reporter is activated by 30 and 100nM TCDD when IM-9 cells 
are cultured to stationary or log concentrations. IM-9 cells were grown to a stationary 
phase (cell concentration  1.2 x 10
6
 C/mL) or to a log concentration (~5.0 x 10
5
 C/mL), 
transfected with the 1B luciferase reporter, and then left untreated (NA), or treated with 
DMSO vehicle or TCDD. The vehicle controls for samples treated with 30 nM or 100 nM 
TCDD was 0.019% or 0.1% DMSO. Treatment groups with a log phase final seeding 
concentration were seeded at 5.0 x 10
5
 C/mL. Treatment groups with a stationary phase 
final seeding concentration were seeded at 1.0 x 10
6
 C/mL and incubated for 24h. 
Luciferase activity was measured in relative light units. Statistical significance was 
determined by Two-way ANOVA followed by a Bonferroni’s two-tailed t test (95% 
confidence intervals) indicated and is depicted by “*” (p<0.05) or “**” (p<0.01).  
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Figure 14. The fold-activation of the 1B and 1C reporters is slightly higher in IM-
9 cells initially cultured to a stationary phase versus a log phase. IM-9 cells were 
grown to a stationary phase (cell concentration  1.2 x 10
6
 C/mL) or to a log 
concentration (~5.0 x 10
5
 C/mL), then transfected with either the 1B or 1C luciferase 
reporters, and then left untreated (NA), or treated with 0.019% DMSO vehicle (DMSO) 
or 30 nM TCDD (TCDD). Treatment groups were seeded at 1.0 x 10
6
 C/mL and 
incubated for 24h. Luciferase activity results were normalized to fold change relative to 
vehicle control. Statistical significance was determined by one-way ANOVA followed by 
a Dunnett’s two-tailed t test (95% confidence interval) and is depicted by “*” (p<0.05) or 
“**” (p<0.01). 
  
C
Stationary - Stationary (100 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
Legend
Legend
Legend
F
o
ld
 C
h
a
n
g
e
Stationary - Stationary (30 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
*
NA
Legend
Legend
F
o
ld
 C
h
a
n
g
e
Log - Stationary (100 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
**
F
o
ld
 C
h
a
n
g
e
Log - Stationary (30 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
*
F
o
ld
 C
h
a
n
g
e  
D
Stationary - Stationary (100 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
Legend
Legend
Legend
F
o
ld
 C
h
a
n
g
e
Stationary - Stationary (30 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
*
NA
Legend
Legend
F
o
ld
 C
h
a
n
g
e
Log - Stationary (100 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
**
F
o
ld
 C
h
a
n
g
e
Log - Stationary (30 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
*
F
o
ld
 C
h
a
n
g
e  
B
Stationary - Stationary (100 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
Legend
Legend
Legend
F
o
ld
 C
h
a
n
g
e
Stationary - Stationary (30 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
*
NA
Legend
Legend
F
o
ld
 C
h
a
n
g
e
Log - Stationary (100 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
**
F
o
ld
 C
h
a
n
g
e
Log - Stationary (30 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
*
F
o
ld
 C
h
a
n
g
e  
A
Stationary - Stationary (100 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
Legend
Legend
Legend
F
o
ld
 C
h
a
n
g
e
Stationary - Stationary (30 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
*
NA
Legend
Legend
F
o
ld
 C
h
a
n
g
e
Log - Stationary (100 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
**
F
o
ld
 C
h
a
n
g
e
Log - Stationary (30 nM TCDD)
NA V T
0.0
0.5
1.0
1.5
2.0
2.5
*
F
o
ld
 C
h
a
n
g
e  
60 
 
TCDD activates the human polymorphic hs1,2 enhancer: Once culturing conditions 
for IM-9 transfection studies were optimized we focused our attention on determining  
TCDD-induced effects on the 1A, 1B, 1C, alleles of the hs1,2 enhancer as well as a 
control reporter consisting of the VH promoter alone. We found that the basal activities of 
the human hs1,2 reporters were markedly higher in IM-9 cells versus CH12.LX cells 
(data not shown). In addition we found that in the human IM-9 cell line all three of the 
hs1,2 reporters were activated by TCDD relative to a vehicle control (0.019% DMSO) 
(Fig. 15). These results correspond to the activation of each reporter that was seen in 
CH12.LX cells treated with TCDD. We also compared the averages of TCDD-induced 
fold-activation of the VH promoter and hs1,2 reporters relative to vehicle from multiple 
independent studies in the IM-9 (VH  promoter n=4; 1A n=9; 1B n=11; 1C n= 10) 
and CH12.LX (1A n=4; 1B n=3; 1C n=4) cell lines (Table 2). Converse to our basal 
activity findings, we found a considerably higher increase in the TCDD-induced fold-
activation relative to vehicle of the hs1,2 reporters in CH12.LX versus IM-9 cells (Table 
2). Moreover, the VH promoter was only transfected into IM-9 cells in this study, 
however, the fold-activation of the VH promoter in IM-9 cells was considerably lower 
than the fold activation demonstrated in our previous CH12.LX studies (Fernando et al., 
manuscript in preparation), (data not shown). It is notable, however, that the TCDD-
induced increase in fold-activation of the hs1,2 enhancers compared to the VH promoter 
in IM-9 cells was not statistically significant (Table 2). However our previous studies 
also suggest that the VH promoter may be regulated differently than the hs1,2 reporters 
after treatment with TCDD and LPS in CH12.LX cells. Nevertheless, supposing the 
effect of greater TCDD-induced fold-activation of the hs1,2 reporters in CH12.LX cells 
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versus IM-9 cells is mediated by the AhR, then these findings correspond with previous 
reports of higher AhR affinity and expression in mouse cells versus human cells. 
Furthermore, regardless of the extent of the fold-activation, in both IM-9 and CH12.LX 
cells the fold-activation of the 1B reporter was the highest of the human hs1,2 reporters 
(Table 2), which may be medically relevant to human health based on the association of 
the 1B allele of the hs1,2 enhancer to several autoimmune diseases. In total our data 
demonstrates that the human hs1,2 enhancers are activated by TCDD in a human B-cell 
line model. 
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Figure 15. The human hs1,2 reporters are activated by TCDD in human IM-9 cells. 
The VH, 1A, 1B or 1C reporters were transfected into IM-9 cells then left untreated 
(NA) or treated with 0.019% DMSO vehicle control (DMSO) or 30nM TCDD (TCDD) 
and  incubated for 24 h. The results depicted are not from the same study. Luciferase 
activity results are reported in relative light units and are normalized to the activity of the 
DMSO vehicle treatment group of each plasmid. Statistical significance was determined 
by one-way ANOVA followed by a Dunnett’s two-tailed t test (95% confidence interval) 
and is depicted by “**” (p<0.01). 
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  CH12.LX (30 nM TCDD) IM-9 (30 nM TCDD) 
Reporter Fold-
activation  
 
±SEM p-value Fold-
activation  
±SEM p-value 
VH † † † 1.2 0.058 p>0.05 
1A 1.9 0.313 p>0.05 1.4 0.066 p<0.01 
1B 2.6 0.231 p<0.01 1.6 0.116 p<0.001 
1C 1.8 0.288 p>0.05 1.5 0.078 p<0.001 
 
 
 
Table 2. Comparisons of TCDD-induced fold-activation relative to vehicle control of 
the VH promoter alone and the hs1,2 reporters in CH12.LX or IM-9 cells. 
Comparison of the average fold-activation induced by 30 nM TCDD relative to the 
0.019% DMSO vehicle control from multiple transfection studies of the 1A, 1B, and 
1C human reporters in unstimulated CH12.LX cells (1A n=4; 1B n=3; 1C n=4) 
versus unstimulated IM-9 cells (1A n=9; 1B n=11; 1C n= 10). Transfection studies 
utilizing the VH reporter alone were not conducted in CH12.LX cells, as symbolized by 
“†.”Significance was calculated by 1-way ANOVA followed by a Dunnett’s two-tailed t 
test (95% confidence interval). 
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The human hs1,2 enhancer is not activated by CpG 
In our past CH12.LX transfection studies we found a correlation between the number of 
53bp repeats of each allele of the human hs1,2 enhancer and a LPS-induced increase in 
the total activity of the VH promoter and human hs1,2 reporters (Fernando et al., 
manuscript in preparation). Furthermore, we found that the human hs1,2 enhancer was 
synergistically activated by TCDD and LPS co-treatment in CH12.LX cells (Fernando et 
al., manuscript in preparation). Therefore, we decided to determine if the synergistic 
activation from stimulation and TCDD treatment is also displayed in human IM-9 cells. 
Although, we did not see an appreciable level of cellular activation of IM-9 cells treated 
with CpG in our characterization studies, our preliminary experiments demonstrated a 
slight CpG-induced activation of transcriptional activity of the human 1B reporter in 
IM-9 cells (data not shown). Thus, we employed CpG as a stimulant for our transfection 
studies. However, our data suggests that the transcriptional activation of the 1B reporter 
is not enhanced in IM-9 cells co-treated with CpG and TCDD (Fig. 16).  
 
  
65 
 
 
1B reporter in IM-9 cells
NA DMSO TCDD CpG C+D C+T
0
5000
10000
15000
20000
** **
L
u
c
if
e
ra
s
e
 A
c
ti
v
it
y
(r
e
la
ti
v
e
 l
ig
h
t 
u
n
it
s
)
1B reporter in CH12.LX cells
NA DMSO TCDD LPS L+D L+T
0
500
1000
1500
2000
2500
***
***
L
u
c
if
e
ra
s
e
 A
c
ti
v
it
y
(r
e
la
ti
v
e
 l
ig
h
t 
u
n
it
s
)
 
Figure 16. LPS and TCDD co-treatment synergistically activates the 1B reporter 
in CH12.LX cells but CpG treatment does not enhance TCDD-induced activation of 
the 1B reporter in IM-9 cells. A, Luciferase activity of the 1B reporter was measured 
in untreated human IM-9 B cells (NA) or IM-9 cells treated for 24 h with 0.019% DMSO 
vehicle control (DMSO), 30 nM TCDD (TCDD), 0.5 M CpG (CpG), 0.5 M CpG + 
0.019% DMSO (C+D), or 0.5 M CpG + 30 nM TCDD (C+T). B, Luciferase activity of 
the 1B reporter was measured in untreated mouse CH12.LX cells (NA) or CH12.LX 
cells treated for 24 h with 0.019% DMSO vehicle control (DMSO), 30 nM TCDD 
(TCDD), 1 g/mL LPS (L), 1 g/mL LPS + 0.019% DMSO (L+D) or 1 g/mL + 30 nM 
TCDD (L+T). Statistical significance was determined by one-way ANOVA followed by 
a Dunnett’s two-tailed t test (95% confidence interval) and is depicted by “**” (p<0.01) 
or “***” (p<0.001). 
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BSAP decreases TCDD-induced activity of the human hs1,2 enhancer 
Mouse models are widely used for toxicological studies based on their overall 
genetic similarity to humans. As stated previously, the human and mouse hs1,2 enhancers 
share a 90% core sequence identity (Mills et al. 1997). However, differences between the 
human and mouse hs1,2 enhancer sequences may impact their transcriptional regulation. 
Our previous data has shown that TCDD inhibits LPS-stimulated transcriptional 
activation of a luciferase reporter consisting of the mouse hs1,2 enhancer in the mouse 
CH12.LX cell line (Fernando et al. manuscript in preparation).  Conversely, in CH12.LX 
cells the human hs1,2 luciferase reporters are activated by TCDD in the absence of 
stimulation and synergistically activated by a TCDD and LPS co-treatment (Fernando et 
al. manuscript in preparation). The primary sequence difference between the human and 
mouse hs1,2 enhancers is the lack in the human hs1,2 sequence of the high affinity BSAP 
site found in the mouse hs1,2 enhancer sequence (Mills et al. 1997). BSAP is an inhibitor 
of B-cell differentiation (Nutt et al. 1999). In immature and mature B cells BSAP 
expression is high, but during the differentiation process BSAP expression is reduced to 
nil in plasma cells (Reviewed by Nutt et al. 2001). BSAP in conjunction with κB and Oct 
motifs exert a concerted repression of the mouse hs1,2 enhancer in mature B cells (Singh 
and Birshtein 1993, 1995; Michaelson et al., 1996). This is contrary to what is seen in 
plasma cells where BSAP is not expressed and protein binding to the B and Oct motifs 
within the mouse hs1,2 enhancer exhibits a positive effect (Michaelson 1996). Moreover, 
Yoo et al. (2003) demonstrated that in CH12.LX cells co-treated with LPS and TCDD, 
expression of BSAP protein and mRNA was maintained 72h post LPS-activation. The 
TCDD-induced sustained expression of BSAP could have inhibited the change in role of 
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κB and Oct which positively regulate B cells late in differentiation. This prolonged 
expression of BSAP and hence, negative regulation by BSAP, was correlated with a 
decrease in IgH transcripts (Yoo et al. 2003). Together these conclusions led us to the 
hypothesis that in TCDD-treated cells, the lack of the high affinity BSAP site in the 
human hs1,2 enhancer when compared to the mouse hs1,2 enhancer could mediate the 
differences in transcriptional modulation by TCDD. Therefore, oligonucleotide primers 
were designed to add a BSAP site, identical to the high affinity BSAP site in the mouse 
hs1,2 enhancer, to the wild type human 1A reporter (1A+BSAP) by site directed 
mutagenesis (Fernando et al,. manuscript in preparation). We then conducted transient 
transfection experiments using the 1A and the 1A+BSAP reporters in IM-9 cells and 
we found that both reporters were activated by TCDD. We found that, the TCDD-
induced fold-activation of the 1A+BSAP was noticeably lower than the fold-activation 
of the 1A reporter (Fig. 17). Therefore, our results suggest that the 1A+BSAP reporter 
may be negatively regulated by the added BSAP motif. This is supported by studies from 
our lab of 1A+B reporter transfected into the mouse CH12.LX cell line, in which the 
1A+BSAP reporter demonstrated a consistent decrease in total TCDD-induced 
activation versus the 1A reporter in LPS induced CH12.LX cells (Ochs et al., 
manuscript in progress).   
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Figure 17. TCDD-induced activation of the human hs1,2 enhancer is inhibited by 
addition of a BSAP binding motif. IM-9 cells were transfected with the 1A (A) or 
1A + BSAP (B) reporters then left untreated (NA) or treated with 0.019% DMSO 
vehicle control (DMSO) or 30 nM TCDD (TCDD) and incubated for 24 h. Luciferase 
activity was normalized to fold change in activity relative to VH. Statistical significance 
was determined by one-way ANOVA followed by a Dunnett’s two-tailed t test (95% 
confidence interval) and is depicted by “*” (p<0.05) or “***” (p<0.001). 
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DISSCUSION 
The IM-9 cells are an acceptable but not ideal cellular model for mechanistic studies 
on the effects of TCDD on the 3’IgHRR  
 The 3’IgHRR has been established as a mediator of VDJ rearrangement (Serwe 
and Sablitzky, 1993), CSR (Bottaro et al., 1998; Pattersson et al., 1990; Lieberson et al., 
1991; Darizvach et al., 1991; Cogné et al., 1994) and Ig expression and secretion (Wabl 
et al, 1984; Klein et al., 1984) through transcriptional regulation of the IgH gene. Our 
previous studies suggest that expression and secretion of Ig may be inhibited by TCDD, 
possibly through the AhR pathway (Sulentic et al., 1998; 2000). We previously 
hypothesized that the AhR pathway and binding of AhR/ARNT to DRE motifs may be 
one mechanism behind TCDD-induced modulation of the mouse 3’IgHRR and individual 
enhancers in activated CH12.LX cells. We have identified DRE-like motifs within the 
hs4 of the mouse and hs1,2 of the mouse and human 3’IgHRR (Sulentic et al., 2000; 
Fernando et al., manuscript in preparation). We also found that, in the LPS-activated 
mouse CH12.LX cell line, TCDD modulates the transcriptional activity of luciferase 
reporter plasmids consisting of the mouse hs4 enhancer and 3’IgHRR as well as the 
mouse and human1,2 enhancers of the 3’IgHRR (Sulentic et al., 2004a, 2004b; Fernando 
et al., manuscript in preparation). However, this study is the first to explore the use of a 
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human cell line as a model for mechanistic studies on the effects of TCDD on the human 
hs1,2enhancer of the 3’IgHRR. We found that the IM-9 cell line may be a suitable, but 
not an ideal model for our 3’IgHRR studies. Our data suggests that IM-9 cells possess a 
functional AhR pathway, as we identified AhR expression and established TCDD 
induction of the CYP1A1 gene in IM-9 cells. In a previous study, the expression of AhR 
was not confirmed in the IM-9 cell line due to conflicting results in which TCDD induced 
binding of AhR and ARNT protein to a DRE from the CYP1A1 gene, as identified by 
supershift analysis in an EMSA study, but AhR was not detected by Western blot 
(Masten and Shiverick, 1996). We believe our confirmation of AhR expression in IM-9 
cells can be attributed to increased specificity and affinity of anti-AhR antibody since the 
time of the previous IM-9 cell study (Masten and Shiverick, 1996). Still, identifying AhR 
required us to load high concentrations of total IM-9 protein in our Western blot assay, 
and the expression level of AhR coincided with the considerably lower induction of 
CYP1A1 when compared to what is seen in the mouse CH12.LX cells (Sulentic et al., 
2000). The lowered induction of CYP1A1 supports the theory that human AhR has lower 
expression and binding affinity for TCDD than mouse AhR (Harper et al., 1988; Ema et 
al., 1994; Reviewed by Connor and Aylward, 2006) which may influence the level of 
TCDD-induced CYP1A1 expression and resultant toxic effects. Interestingly, our results 
contrast with the Nohara et al. study (2006) which suggested that TCDD induced higher 
levels of CYP1A1 induction in primary human lymphocytes versus AhR high affinity 
C57BL/6 (C57) mouse cells. However, differences in CYP1A1 induction are related to 
AhR expression and several polymorphisms of human AhR with varied binding affinity 
to TCDD have demonstrated cell-type specificity in human tonsils, hepatocytes, placenta 
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(Lorenzen and Okey, 1991; Lesca et al., 1994; Okey et al 1997). Thus, AhR binding 
affinity to TCDD may differ between primary lymphocytes and the IM-9 B cell line. 
Additionally, several laboratories have demonstrated that lowered expression of CYP1A1 
could also be dependent on several factors along the AhR pathway other than AhR 
affinity, including coactivators (Fuji-Kuriyama and Mimura, 2005; Hankinson, 2005; 
Kim and Stallcup, 2004), chaperone proteins (Carlson and Perdew, 2002; Cox and Miller, 
2003), and cross-talk between AhR and other transcription factors (Beishlag and Perdew, 
2005; Marlowe and Puga, 2002).  
In parallel with our previous findings that TCDD-treatment may inhibit Ig 
expression and secretion in activated mouse CH12.LX cells, possibly through the AhR 
pathway (Sulentic et al., 1998, 2000), we hypothesize that TCDD may also inhibit Ig 
secretion in an activated human cell line. In order to analyze TCDD-induced differences 
in Ig expression and secretion, an ideal human cell model should express basal and/or 
inducible Ig. We evaluated basal Ig in IM-9 cells and found a level of basal Ig secretion 
that was contrary to what was previously reported by the Fahey et al. study (1971), in 
which IM-9 cells were characterized as high Ig secreting lymphoblast but not plasma 
cells. In their study they utilized a complex culturing pattern in order to induce high 
amounts of basal IgG. We followed the culturing pattern illustrated in their 1971 study 
(Fahey et al., 1971), however their resulting antibody secretion was orders of magnitude 
higher than our findings, (hundreds of ng per 10
6
 cells versus ng per 10
6
 cells). This 
quantitative difference in IgG expression was perplexing, and could have been due to 
unspecified culturing practices or IM-9 cell line differentiation. The lymphoblast phase of 
development means that the B cell has encountered antigen but has not differentiated into 
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plasma cells which would be demonstrated by high amounts of endoplasmic reticulum 
within the cell and high levels of Ig secretion. Even though the IM-9 cells in the Fahey 
study (1971) started off in a lymphoblast stage of development, their IM-9 cell cultures 
were maintained at considerably high cell concentrations (2 - 3 x 10
6
 C/mL) for extended 
periods of time (10 -12 days). Perhaps, several days of such high cell culture 
concentrations are necessary to initiate an antibody response in IM-9 cells. However, 
these same conditions could have led to differentiation of the Fahey IM-9 cells into 
plasma cells, and concordantly the high levels of Ig that we did not see. Interestingly, in 
our 96 h Ig secretion studies in IM-9 cells we saw low but increasing numbers of larger 
than average cells with cellular structures visible at a 1000X magnification, possibly 
endoplasmic reticulum, after 60 h that would suggest the onset of cellular differentiation. 
One report has suggested that change in phenotype of B cells during extended periods of 
culture may be due to interactions with stimulatory fragments of Ig Fc regions that have 
been secreted into cell media (Hobbs et al., 1985, 1989). Contamination is also a 
possibility, as one report stated that one of the biggest problems encountered in cell 
culture is infection with mycoplasmas (Drexler et al., 1999), which has also been 
associated with differentiation of B cells (Sitia et al., 2005). Alternatively to a possible 
phenotype change within the Fahey study (1971), our initial culture of IM-9 cells from 
ATCC could have a different phenotype with respect to the reported phenotype of the 
IM-9 cells. For example, the IM-9 cells we cultured may have already differentiated into 
memory B cells, and studies with in vivo mouse B cells have suggested that memory B 
cells may only secret high levels of IgG if activated by cell specific antigen in addition to 
TLR activation (Richard et al., 2008; reviewed by Lanzavecchia and Sallusto, 2009). This 
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may be why they were not activated to secrete Ig by the TLR 9 agonist CpG or the TLR7 
agonist R848 which have both reported to be activators of B cell lines (Bauer et al., 2001; 
Bishop et al., 2001). In light of this premise the IM-9 cells may be activated only if they 
are treated with the TLR9 agonist CpG or TLR7 agonist R848 in conjunction with, anti-
IgG, anti CD40 or CD40L, and/or stimulatory cytokines (i.e. IL-4 or IL-9). Thus, the 
limited IgG expression in IM-9 cells could hinder determining TCDD-induced effects on 
Ig expression which makes IM-9 the cell line a less than ideal human B-cell model. 
However, the IM-9 cells still have a functional AhR pathway which supports the use of 
them for mechanistic studies of TCDD in the transcriptional regulation of the 3’IgHRR. 
 
The human polymorphic hs1,2 enhancer is activated by TCDD in human IM-9 cells 
As stated above, the AhR pathway is thought to end in AhR/ARNT binding to 
DRE motifs in promoter regions of several genes (Whitlock, 1990). We previously 
identified DRE motifs within the hs4 and the mouse and human hs1,2 enhancers of the 
3’IgHRR which may be sensitive targets of TCDD. More specifically, we found that 
TCDD activates the mouse hs4, but inhibits the mouse 3’IgHRR. Additionally, although 
the human and mouse hs1,2 enhancers share a 90% similarity (Mills et al., 1997), TCDD 
inhibits the activity of a reporter consisting of the mouse hs1,2 enhancer, but activates the 
human hs1,2 reporter in LPS activated and TCDD-treated IM-9 cells (Sulentic et al., 
2000; Fernando et al., manuscript in preparation). This study resolves the question of 
whether this divergence in transcriptional activation between the mouse and human hs1,2 
enhancers in mouse CH12.LX cells was cell model related, by demonstrating that 
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reporters consisting of the human polymorphic hs1,2 enhancer are also activated by 
TCDD in IM-9 cells. However the TCDD-induced activation seen in human IM-9 cells 
did not mirror what was seen in mouse CH12.LX cells. One key difference was that the 
basal activity of each of the human hs1,2 reporters was magnitudes higher than the 
activity seen in the CH12.LX cells. This difference could have been cell model related in 
that human IM-9 cells may possess cellular machinery (i.e. RNA polymerase, basal 
transcription factors) that is more equipped to activate the human hs1,2 reporters, as 
mouse cellular machinery may more effectively activate the mouse hs1,2 reporter. This 
theory is supported by a study from Chen and Birshtein (1997) in which they observed 
that reporters consisting of the human C1 3’IgHRR and C2 3’IgHRR demonstrated 
more basal activity than the mouse hs1,2 enhancer in a human plasma cell line. On the 
other hand, the mouse hs1,2 enhancer was more basally activated in a mouse plasma cell 
line than the human C1 and C2 3’IgHRR (Chen and Birshtein, 1997). Whereas the 
human hs1,2 reporters demonstrated the greatest basal activity in human IM-9 cells, the 
greatest fold change in TCDD-induced activation of the human hs1,2 reporters was 
demonstrated in mouse CH12.LX cells. This difference could have also been cell model 
related in that the AhR has been found to be species specific in several animal models 
including, mouse, guinea pig, rat and others (reviewed by Connor and Aylward, 2006). In 
most cases human AhR has demonstrated considerably lower binding affinities and 
expression levels than other animal models (reviewed by Connor and Aylward, 2006), 
which may have influenced the extent of TCDD-induced inhibition. Although we saw 
differences in levels of basal activity and in TCDD-induced fold-activation of the human 
hs1,2 reporters in IM-9 and CH12.LX cells, we found that the 1B reporter demonstrated 
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the greatest TCDD-induced fold-activation in both IM-9 and CH12.LX cells. This finding 
is relevant because of the multiple autoimmune diseases that have been associated with 
the expression of the 1B enhancer of the hs1,2 enhancer, including: IgA nephropathy 
(IgAN) (Aupetit et al., 2000), Celiac disease, systemic sclerosis, schizophrenia, dermatitis 
herpetiformis, plaque psoriasis (Frezza et al., 2004,2007, 2009), psoriatic arthritis (Cianci 
et al., 2008), and rheumatoid arthritis (Tolusso et al., 2009). Several studies suggest a 
correlation with the 1B allele of the hs1,2 enhancer  and  immune deregulation of the 
IgA1 isotype which relates to our work in that we believe TCDD is a modulator of 
immune regulation through the 3’IgHRR, and we have shown altered regulation of Ig 
expression and function by TCDD (Sulentic et al., 1998, 2000). As discussed above we 
did not identify an ideal stimulant for IM-9 cells so we were unable to compare the 
effects of TCDD in activated CH12.LX and activated IM-9 cells. However, since the 
human hs1,2 reporters still demonstrated TCDD-induced activation in IM-9 cells as well 
as in unstimulated mouse CH12.LX cell, these results are significant because they 
support the applicability of TCDD mechanistic studies of the 3’IgHRR in mouse cell 
lines to human application.  
 
BSAP negatively regulates the 1A+BSAP reporter in IM-9 cells treated with 
TCDD  
 As previously stated, the mouse and human hs1,2 enhancers share a 90% 
homology (Mills et al., 1997). However the mouse and human hs1,2 enhancers have a 
divergence in transcriptional regulation in which the mouse hs1,2 enhancer is inhibited 
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by TCDD-induced and LPS co-treated CH12.LX cells, whereas the human hs1,2 
enhancer is activated. In the study above we determined that this divergence is not due to 
differences in cellular models as TCDD activated the human hs1,2 enhancer in both 
mouse CH12.LX cells and human IM-9 cells. Therefore, we hypothesized that minor 
sequence differences could be causing the divergence in transcriptional regulation. We 
utilized the 1A+BSAP reporter, which is the 1A reporter (which has no BSAP site) 
with an added BSAP sequence identical to the high affinity BSAP sequence of the mouse 
hs1,2 enhancer, in order to explore whether the high affinity BSAP site of the mouse 
hs1,2 enhancer is the repressive factor causing the divergence in transcriptional 
regulation of the mouse versus human hs1,2 enhancers. We found that the added BSAP 
site to the 1A reporter lowered TCDD-induced activation compared to the wild type 
1A reporter, which suggests that BSAP exerts an inhibitory role on the 1A+BSAP 
reporter. These results provide supportive evidence that BSAP may, in part, be 
contributing to the TCDD-induced inhibition of the mouse hs1,2 enhancer (contains a 
BSAP site) in LPS-activated CH12.LX B cells as opposed to the TCDD-induced 
activation of the human hs1,2 enhancer (no BSAP site). This hypothesis is also supported 
by preliminary studies in our lab in which the 1A+BSAP enhancer compared to the 
1A reporter demonstrates a significant decrease in total activity in the mouse CH12.LX 
cells (Ochs et al., unpublished data). BSAP inhibition could have occurred through the 
recruitment of Groucho family proteins, which are co-repressive proteins reported to 
localize with BSAP and repress gene transcription (reviewed by Fisher and Caudy, 1998; 
Parkhurst, 1998). Additionally, BSAP could have competed for recruitment of general 
transcription factors (TBP and TFIIF), which AhR has also been shown to recruit 
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(Rowlands et al., 1996). Interestingly, the total activation of the human hs1,2 enhancer 
was not completely ablated by the addition of the BSAP site in either cell line. This 
finding may have been due to the collective activation by NFκB, AP-1, and Oct that we 
found in our previous site directed mutational studies on the human hs1,2 reporter in LPS 
and TCDD co-treated CH12.LX cells (Fernando et al., manuscript in preparation). 
Notably in our earlier studies we also found that the DRE exerts a slightly inhibitory 
effect (Fernando et al., manuscript in preparation) on the human hs1,2 reporter. 
Importantly, inhibition of the mouse hs1,2 enhancer may have been due to additional 
factors besides the high affinity BSAP site we added to the 1A reporter. For instance, a 
second low affinity BSAP site is located on the mouse hs1,2 enhancer (Singh and 
Birshtein, 1993; Mills et al., 1997), and full repression of basal activity of the hs1,2 
enhancer has been reported to be seen only when both BSAP sites are occupied (Singh 
and Birshtein, 1996). In addition, an NFP site, an ETS-like family motif and positive 
regulator of the mouse hs1,2 enhancer, is located adjacent to a BSAP site of the mouse 
hs1,2 enhancer (Neurath et al., 1995). NFP has demonstrated reciprocal binding with 
the high affinity BSAP site. More specifically, in mature B cells, binding of the BSAP 
site of the mouse hs1,2 enhancer blocks the NFP site and, therefore, inhibits the basal 
activity of the mouse hs1,2 enhancer (Neurath et al., 1995). On the other hand, in plasma 
cells, where BSAP is not expressed, binding to NFP is not blocked which increases the 
activity of the mouse hs1,2 enhancer resulting in increased mRNA transcripts (Neurath et 
al., 1995). However, while this may explain a possible mechanism of the BSAP-mediated 
repression of the mouse hs1,2 enhancer, it does not explain the BSAP-mediated 
repression we saw of the human 1A+BSAP reporter, as the human hs1,2 enhancer does 
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not contain a NFP site. Although the mechanism behind the inhibition of the mouse 
hs1,2 enhancer remains unclear, our data strongly supports the theory that BSAP is a 
primary mediator behind the transcriptional divergence between the mouse and human 
hs1,2 enhancers. 
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CONCLUSION 
Our results support the use of the IM-9 cell line as a model for mechanistic 
studies on the effects of TCDD on the human 3’IgHRR, as evidenced by AhR expression 
and TCDD-mediated induction of the CYP1A1 gene. Our IM-9 cells demonstrated a 
different phenotype then previously reported in that they expressed only low levels of 
IgG. Moreover IM-9 cells were not activated by CpG, through TLR9, or R848, through 
TLR7. However, since increased AhR expression may result in increased B cell 
sensitivity to TCDD and activation of the AhR pathway, in our in future studies we may 
attempt to activate IM-9 cells with multiple T-independent and dependant agonist, such 
as a TLR agonist in addition to CD40L, anti-IgG, and/or stimulatory cytokines. Although 
our IM-9 cells only secrete low levels of IgG, they still have the necessary cellular 
machinery to facilitate TCDD-induced expression of the human polymorphic hs1,2 
enhancer. Moreover we found that the human hs1,2 reporter showed significantly higher 
basal activation in the human IM-9 cell line than in the mouse CH12.LX cell line. Yet, 
TCDD induced a greater fold activation of the human hs1,2 reporter in the mouse 
CH12.LX cell line versus the human IM-9 cell line. Notably, the 1B reporter 
demonstrated the greatest TCDD-induced activation in both cell lines. This finding is 
relevant to human health in that immune deregulation of the 1B allele of the human 
hs1,2 enhancer has been associated with several human autoimmune diseases and TCDD-
induced modulation of the 1B allele via the AhR pathway could be one mechanism in 
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the etiology of the reported diseases. Regardless of the differences in level of basal and 
TCDD-induced activity, our findings of TCDD-induced activation of the human hs1,2 
reporter in both IM-9 and CH12.LX cell lines support the use of the human IM-9 cell line 
for mechanistic studies of TCDD-induced effects of the human hs1,2 enhancer. One 
future study that could further validate this conclusion would be to transfect the mouse 
hs1,2 reporter into human IM-9 cells in order to compare the trend in TCDD-induced 
effects to our previous observations in the mouse CH12.LX cell line. In addition to 
demonstrating the similarities and differences in the activity of the human hs1,2 reporter 
transfected into IM-9 and CH12.LX cell lines, we demonstrated that the BSAP site in the 
mouse hs1,2 enhancer may be contributing to the inhibitory effect of TCDD on the 
mouse versus human hs1,2 reporter. This theory is supported by the decrease in TCDD-
induced activation of the 1A allele of the human hs1,2 enhancer with the addition of a 
BSAP binding site. To study this further we could explore the effects of deleting the high 
affinity BSAP site from the mouse hs1,2 reporter and transfect this mutated reporter into 
the mouse CH12.LX cell line. In conclusion, our results that TCDD modulates the 
activity of the human hs1,2 enhancer in the human IM-9 cell line are highly relevant due 
to the fact that TCDD is environmentally persistent, and the reports that the AhR pathway 
is activated by several exogenous and endogenous chemicals and pharmaceuticals in 
addition to TCDD (Hensler et al., 2009; Flaveny et al., 2009), thus warranting continued 
study on the impact of TCDD on the human 3’IgHRR in the human IM-9 cell line. 
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